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Sarcomas are a broad family of mesenchymal malig-
nancies exhibiting remarkable histologic diversity.
We describe the multi-platform molecular landscape
of 206 adult soft tissue sarcomas representing 6
major types. Along with novel insights into the
biology of individual sarcoma types, we report
three overarching findings: (1) unlike most epithelial
malignancies, these sarcomas (excepting synovial
sarcoma) are characterized predominantly by copy-
number changes, with low mutational loads and
only a few genes (TP53, ATRX, RB1) highly recur-
rently mutated across sarcoma types; (2) within sar-
coma types, genomic and regulomic diversity of
driver pathways defines molecular subtypes associ-
ated with patient outcome; and (3) the immune
microenvironment, inferred from DNA methylation
and mRNA profiles, associates with outcome and
may inform clinical trials of immune checkpoint
inhibitors. Overall, this large-scale analysis reveals
previously unappreciated sarcoma-type-specific
changes in copy number, methylation, RNA, and pro-
tein, providing insights into refining sarcoma therapy
and relationships to other cancer types.
INTRODUCTION
Adult soft tissue sarcomas (henceforth referred to collectively as
sarcomas) are diverse mesenchymal malignancies that account
for 1% of adult solid tumors. Many are highly aggressive, ac-
counting for a disproportionate share of cancer mortality among
young adults (ages 20–39, in SEER data, https://seer.cancer.
gov). Sarcomas are typically classified according to the normal
mesenchymal tissue they most resemble. They comprise more
than 70 types that differ in pathologic and clinical features. Sar-
comas fall into two broad genetic groups: those with simple kar-
yotypes harboring specific genetic alterations (translocations,
activating mutations) and those with complex karyotypes (Taylor
et al., 2011a). For The Cancer Genome Atlas (TCGA) sarcoma
analysis, we focused on 6 major adult soft tissue sarcomas,
including 5with complex karyotypes: (1) dedifferentiated liposar-
coma (DDLPS), an undifferentiated sarcoma usually arising in as-950 Cell 171, 950–965, November 2, 2017 ª 2017 The Authors. Publi
This is an open access article under the CC BY-NC-ND license (http://sociation with well-differentiated liposarcoma and characterized
by 12q1315 amplification; (2) Leiomyosarcoma (LMS), showing
smooth muscle differentiation, arising in both gynecologic
(ULMS) and soft tissue (STLMS) sites; (3) undifferentiated
pleomorphic sarcoma (UPS), lacking any defined line of differen-
tiation; (4) myxofibrosarcoma (MFS), showing fibroblastic differ-
entiation with myxoid stroma; (5) malignant peripheral nerve
sheath tumor (MPNST), which arises in peripheral nerves. The
sixth type was a simple-karyotype sarcoma, synovial sarcoma
(SS), defined by the translocation t(X;18)(p11;q11). We inte-
grated genome-scale analyses of mRNA, microRNA (miRNA),
protein, and alterations of DNA sequence, methylation, and
copy number to understand the genomic diversity of oncogenic
drivers, to refine clinical risk stratification, and to identify poten-
tial therapeutic targets.
RESULTS AND DISCUSSION
Samples and Clinicopathologic Data
We studied 206 sarcomas with diagnoses confirmed by expert
pathology review: 80 LMS (53 STLMS and 27 ULMS), 50 DDLPS,
44UPS, 17MFS, 10SS, and5MPNST (Figures1AandS1A). Clin-
ical and pathologic data are summarized in Figure 1A and Table
S1. The median age at diagnosis was 60 years (range 20–90).
Sarcomas were mostly intermediate to high grade (93%) and
84% arose in deep soft tissue (or uterine and visceral sites).
Pan-sarcoma Molecular Analysis
Adult Soft Tissue Sarcomas Harbor Frequent
Copy-Number Alterations
Mutational profiles and genomic alterations in the 6 sarcoma
types are summarized in Figure 1A and Table S1. Unsupervised
cluster analysis of somatic copy-number alterations (SCNAs)
divided cases into 6 major clusters; C2 with relatively few unbal-
anced segments, consisting mostly of DDLPS and SS; C3, con-
sisting mostly of DDLPS with complex copy-number alterations;
C4 andC5, dominated by LMS; andC1 and C6 consistingmostly
of UPS and MFS (Figure S1B).
SCNAs frequently affected the MDM2-p53 and the p16-
CDK4-RB1 pathways. MDM2 amplification was present in all
DDLPS by definition, and deep deletions (as defined in the
STAR Methods) of TP53 were found in 9% of LMS, 16% of
UPS, and 12% of MFS. In the RB pathway, deep deletions of
RB1 were detected in 14% of LMS, 16% of UPS, and 24%
of MFS; deep deletions of CDKN2A (p16) were found in 8% ofshed by Elsevier Inc.
creativecommons.org/licenses/by-nc-nd/4.0/).
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LMS, 20% of UPS, and 18% of MFS. RB pathway alterations in
DDLPS included CDK4 amplification in 86% and CDKN2A deep
deletion in 2%. Overall, the complex karyotype sarcomas were
characterized by frequent SCNAs compared to most other
TCGA tumor types (Figures 1B, S1C, and S1D). DDLPS showed
the highest frequency of SCNAs of any tumor type, due to
its highly recurrent focal amplifications at 12q1315. In contrast,
SS displayed very few SCNAs or mutations.
Analyses for fusion transcripts identified either SS18-SSX1 or
SS18-SSX2 fusions in all SS cases. We also found recurrent fu-
sions of TRIO to TERT (n = 3) or to other genes (n = 2) (Figure 1A),
as recently reported (Delespaul et al., 2017). Cases with TRIO-
TERT fusions had the highest TERT expression across all sar-
comas (Figure S1E).
Adult Soft Tissue Sarcomas Have Low Somatic Mutation
Burdens
The overall somatic mutation burden in these 206 sarcomas was
low (average 1.06 per Mb; Figures 1A, 1B, S1D, and S2A). We
applied MuSiC analysis (Dees et al., 2012) to whole-exome
sequencing (WES) data to identify significantly mutated genes
(SMGs), i.e., genes with a statistically higher-than-expected mu-
tation prevalence across the entire cohort (false discovery rate
[FDR] <0.05). This identified only 3 SMGs: TP53, ATRX, and
RB1 (Figure 1A). TP53 mutations were most prevalent in LMS
(40 of 80). RB1 mutations were seen in LMS, UPS, and MFS.
We surveyed known cancer genes for potential driver muta-
tions and found that 138 sarcomas (67%) contained at least
one variant in a gene known to be involved in cancer progres-
sion, although few of these were in known cancer hotspots (Fig-
ure 2A). Potentially functional mutations included truncating
mutations inNF1 (n = 3),NF2 (1), and PRKDC (4), a gene involved
in telomere stabilization and critical for double-strand break
repair (Figure 2B). As ATRX, TP53, and PRKDC mutations may
disrupt telomere maintenance, we inferred telomere lengths
from WES data using TelSeq (Ding et al., 2014). Outlier analysis
identified telomere lengthening in 24 cases, mostly LMS and
UPS/MFS (Table S2), with no association with TP53 or PRKDC
mutation. In UPS/MFS, long telomeres were associated with
ATRX deletion or mutation (p = 0.013), as recently reported
(Liau et al., 2015).
Assessment of mutational processes in samples with low
mutation burden is a significant challenge. To alleviate this limi-
tation, we used a two-step procedure. First we used de novo
signature discovery in 205 WES and 37 whole-genome
sequencing (WGS) samples to identify the mutational processes
in the cohort (Figure S2B). This process identified predominant
signatures similar to COSMIC 1, 3, 5, and 13 (http://cancer.
sanger.ac.uk/cosmic/signatures), with the exception of the two
tumors with the highest mutational burden, in which theFigure 1. Landscape of Genomic Alterations in 206 Sarcomas
(A) Integrated plot of clinical andmolecular features for all samples, ordered by sar
mutational signatures, indicating type of substitution; patient sex; sarcoma grad
ments; tumor site; sarcoma type; cluster from iCluster analysis; significantly mu
MuSiC2; TRIO or SS18-SSX gene fusions; frequent focal somatic copy-number a
or deep deletion (dark blue). The key to the color coding of sarcomas and mutat
(B) Median numbers of unbalanced copy-number segments versus nonsynonym
See also Figure S6.
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and that respectively showed frameshift mutation in MSH6 and
low MSH2 expression (Figure S2C). The second step used
established COSMIC signature profiles 1, 3, 5, and 13 to quantify
the mutational signatures in the WES data (Figure 3A). Of the
mutations, 90% were attributable to COSMIC5 (53%) and
COSMIC1 (37%). COSMIC2 and 13 (evidence of APOBEC
mutagenesis) were modestly elevated in DDLPS and MPNST
compared to other types (p < 106 by Kruskal-Wallis; Figure 3B).
COSMIC1 and COSMIC5 are clock-like mutational processes,
occurring continuously over a patient’s lifetime (Alexandrov
et al., 2015), and we found their contributions to the mutational
profiles to be correlated with age at diagnosis in DDLPS (Pear-
son correlation 0.38, p = 0.006), MFS (Pearson correlation
0.52, p = 0.04), and STLMS (Pearson correlation 0.43,
p = 0.001; Figure S2D). Thus, sarcomas have a low mutation
burden, and the mutations present in some sarcomas predomi-
nately reflect age-related C > T mutations at CpG dinucleotides,
likely representing passenger mutations.
Genomic Correlates of Computational Morphometrics
To determine if genomic complexity is reflected in nuclear pleo-
morphism (i.e., highly variable nuclear area), a common feature
of complex karyotype sarcomas, we used automated computa-
tional analysis of whole-slide digital pathology images, to calcu-
late a nuclear pleomorphism score as the variance of nuclear
area for each patient (Figure S2E). Increased nuclear pleomor-
phism correlated significantly withmultiplemeasures of genomic
complexity: number of whole genome doublings (p = 0.003,
ANOVA; Figures 3C and 3D), subclonal genome fraction
(p = 4e-6), and aneuploidy score based on the number of arms
with gains or losses (p = 5e-6, Pearson correlation) (Figure S2F).
Our findings provide a genomic basis for this common observa-
tion in cancer histopathology and support the further develop-
ment of computational approaches to digital pathology to
understand additional aspects of tumor morphology.
Integrated Clustering Analyses of Sarcomas
Unsupervised analysis using the cross-platform iCluster tool
(Figure 3E) demonstrated that SS was the most distinct sarcoma
across all platforms. iCluster placed all SS cases into cluster C4,
whose discriminatory features included partial or complete loss
of chromosome 3p in 5 cases (45%), high expression of FGFR3
(p = 7e-20) and miR-183 (p = 2e-25), and methylation of the
PDE4A promoter (p = 1e-06) (Table S3). While SS lacked recur-
rent mutations, it had relatively uniform and unique patterns of
DNA methylation, miRNA expression, and gene expression (Fig-
ures S3A–S3C and S4A), consistent with the proposed central
role of t(X;18)(p11;q11), which results in an SS18-SSX fusion
protein that disrupts epigenetic regulation (Kadoch and Crab-
tree, 2013). The distinct patterns of SS mRNA expression arecoma type. From top to bottom panels indicate: frequency ofmutations perMb;
e; number of whole genome doublings; number of unbalanced genomic seg-
tated genes, defined by false discovery rate (FDR) of <0.05 as computed by
lterations including gains (pink), amplification (red), shallow deletion (pale blue)
ion types is at the bottom. See also Figure S1 and Table S1.
ous somatic mutations in each TCGA cohort. Sarcoma types are color-coded.
AB
(legend on next page)
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illustrated in a schematic 2-D tumor ‘‘map’’ visualization of
high-dimensional mRNA expression data (Figure S4B), where
distances in the map approximate the similarities between the
samples in the original high-dimensional space. The map shows
both SS and LMS as spatially distinct clusters from other
sarcomas.
iCluster C1 was dominated by LMS, 64 of 65 cases (98%),
and was distinguished from other sarcomas largely by genes
linked to myogenic differentiation, including high expression of
MYLK, MYH11, ACTG2, miR-143, and miR-145 (all p < 5e-39)
(Figures S3B, S3C, and S4A). An association with grade was
also noted, with iCluster C1 and C2 containing 11 of the 14
low-grade sarcomas (FNCLCC grade 1) compared to 3 in C3
and none in C4-5 (p = 0.011). However, this effect may be driven
by iCluster separation by histologic type, as 12 of the 14 low-
grade sarcomas were LMS, which was enriched in C1.
Additional differences between LMS and other sarcomaswere
found in protein expression, as shown by the LMS-enriched
RPPA cluster C1 (in which 48 of 53 samples were LMS; Fig-
ure S4C) that showed significantly lower inferred activity of
the apoptosis pathway (p = 1.03e-9), and higher hormone
receptor (ER/PR) levels and inferred PI3K/AKT pathway activity
(p = 1.5e-8 and p = 1.02e-9, respectively) (Figure S4D).
Genomic and Molecular Landscapes of Specific
Sarcomas
Five sarcoma types had sufficient numbers of samples for
detailed analyses of molecular and prognostic subsets, as sum-
marized below. These analyses of prognostic subsets should be
regarded as hypothesis-generating.
DDLPS: Integrated Analyses Suggest Novel Prognostic
Subsets
We first analyzed SCNAs in DDLPS. Then, given the lack of good
biomarkers for aggressive DDLPS, we sought prognostic sub-
sets based on SCNA and DNA methylation data.
Our 50 DDLPS were defined by 12q1315 amplifications,
including highly recurrent copy-number gains or amplification
of MDM2 (100% of our samples), CDK4 (92%), and HMGA2
(76%), as previously reported (Barretina et al., 2010) as well as
FRS2 (96%) and NAV3 (60%). Other frequent SCNAs involved
genes reported to inhibit adipocyte differentiation: JUN (42%)
(Mariani et al., 2007), DDIT3 (32%) (Fawcett et al., 1996), PTPRQ
(46%) (Jung et al., 2009), YAP1 (16%) (Seo et al., 2013), and
CEBPA (24%) (Taylor et al., 2011b) (Figures 4A and 4B; Table
S4). All 5 genes showed correlations between copy number
and mRNA level (p % 0.001; Table S4B). PTPRQ amplification
tended to be mutually exclusive with JUN amplification
(p = 0.026), with only 1 tumor (2%) having amplification of both
genes (Figure 4B). Recurrent deletions (Figure 4A) included
ATRX (10% deep; 20% shallow), NF1 (6% deep; 22% shallow),
and CDKN2A (2% deep; 42% shallow). Given that ATRX mayFigure 2. Mutational Landscape of Sarcomas
(A) Mutations in significantly mutated genes in sarcoma and selected known onc
tations are shown.
(B) Mutation and indel profiles for TP53, ATRX, RB1, NF1, and PRKCD, color-cod
site (exon number + nucleotide position of mutation, e.g., e3+1) or acceptor site
See also Figure S2 and Table S2.
954 Cell 171, 950–965, November 2, 2017be required for response to CDK4 inhibitors (Kovatcheva et al.,
2015) and that 30% of DDLPS have ATRX deletions, ATRX alter-
ationsmay represent an important correlative biomarker in future
clinical trials of CDK4 inhibitors in DDLPS.
To define potentially prognostic subsets of DDLPS, we per-
formed unsupervised clustering of SCNA and DNA methylation
data. The SCNA data yielded 3 distinct clusters; clusters K1
(JUN amplified) and K2 (TERT amplified and chromosomally un-
stable) had worse disease-specific survival (DSS) than K3
(6q25.1 amplified and fewer unbalanced segments than K2
[mean 384 versus 531; p = 0.02]) (Figure S5A). The JUN amplifi-
cation in K1 could contribute to the group’s poor prognosis,
given that JUN overexpression in DDLPS increases migration
and invasion (Sioletic et al., 2014) and that JUN inhibits adipo-
cyte differentiation via repression of CEBPb (Mariani et al.,
2007). Thus, JUN could be an attractive therapeutic target as
agents for its inhibition become available.
Unsupervised consensus clustering of DNA methylation data
defined two clusters: hypomethylated (Meth1) and hypermethy-
lated (Meth2) (Figure 4C). Meth2 had more genome doublings
(p = 0.002) and lower leukocyte fraction (p = 0.0007), and corre-
lated with worse DSS (HR = 4.4; p = 0.002). Meth2 also had
higher inferred content of Th2 cells (Figure S5B), a finding linked
to poor outcomes in other cancers (De Monte et al., 2011).
Integrating the SCNA and methylation clusters, we partitioned
the DDLPS samples into the favorable K3 versus the unfavorable
K1+K2 SCNA clusters, and subdivided the latter into hyperme-
thylated versus hypomethylated cases. The 3 groups differed
significantly in DSS (p = 0.001; Figure 4D); DSS was longest in
the K3 group and shortest in the hypermethylated K1+K2 group,
which showed the lowest inferred fraction of immature dendritic
cells (iDC: p = 0.004) (Bindea et al., 2013) (Figure S5C). While
they require validation, these findings may reflect the impact of
genomic alterations and immune microenvironment on the
behavior of DDLPS, suggest consideration of different treat-
ments for the groups, and provide a rationale for developing
SCNAs and methylation as biomarkers in DDLPS.
LMS: ULMS and STLMS Are Molecularly Distinct
Here, we first examined similarities and differences between
LMS and other sarcomas, then between ULMS and STLMS.
We then defined iCluster subtypes and pathway activities
and explored how the findings could influence treatment
approaches.
As described above, in integrated and individual platform an-
alyses, ULMSand LMSwere generally more similar to each other
than to other sarcomas. Pathway-level alterations included
elevated PI3K/AKT signaling (p = 4e-06), a known feature of
LMS (Gibault et al., 2012), and low apoptosis score (p = 1e-05)
(Figure S6A). We found deletions of the tumor suppressors
TP53 (9% deep and 60% shallow deletions), RB1 (14% deep,
78% shallow), and PTEN (13% deep, 68% shallow) (Figure 5A)ogenes and tumor suppressors. Only genes with recurrent or truncating mu-
ed by sarcoma type. Splice site mutations are indicated as involving the donor
(exon – nucleotide position of mutation).
A E
B
C
D
Figure 3. Mutational Signatures, Genomic Complexity, and Integrated Analysis in Sarcoma
(A) Top: signature activities (number of mutations). Bottom: normalized signature activities, projected onto 3 mutational processes, COSMIC1, COSMIC5, and
APOBEC (COSMIC2 and 13). Tumors are ordered by overall mutation frequency; not shown are the 2 hypermutated samples (AB32 and A9HT) and 1 ultraviolet
signature sample (AB2E).
(B) Left: activities of COSMIC1, COSMIC5, and APOBEC signatures by sarcoma type. Right: normalized signature activity.
(C) Variance in nuclear area according to the number of genome doublings in each tumor.
(D) Representative nuclear area analyses for sarcomas with 0, 1, and 2 whole genome doublings. See also Figures S2E and S2F.
(E) Unsupervised iCluster analysis, which integrated DNA copy number, DNA methylation, and expression of mRNA and miRNA. Color coding of tumor char-
acteristics is at the bottom. Cluster C1 comprised 64 LMS and 1 UPS, including 10 low-grade LMS, and was relatively hypermethylated. Cluster C2 and C3
comprised 49/50 DDLPS and 35 other sarcomas. C4 comprised all 10 SS and one MPNST, and C5 comprised a mix of high-grade sarcomas, with the majority
(34/56) being UPS/MFS. The heatmap scale for copy number is copy number log ratio (tumor versus normal); for methylation is normalized beta value, and for
expression is normalized counts.
See also Figures S3 and S4 and Table S3.
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AC
B
D
Figure 4. Dedifferentiated Liposarcoma
(A) Recurrent focal copy-number alterations in the 50 DDLPS samples byGISTIC 2.0 analysis. Green line indicates the significance threshold (FDR 0.25) for focally
amplified and deleted regions. See also Table S5.
(B) Alterations of genes involved in inhibition of adipose differentiation. The frequency of copy-number alterations in DDLPS is shown for each of the 3 SCNA
clusters, and the heatmap shows gene expression. The scale for gene expression is z-scores from 3 to +3.
(C) Methylation clusters from unsupervised consensus clustering of DNA methylation data in DDLPS. Within methylation clusters, samples are ordered by SCNA
cluster and genome doubling.
(D) DSS in clusters defined by copy number and DNA methylation. See also Figure S4.
See also Figure S5 and Table S4.
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and mutations of TP53 in 50%, RB1 in 15%, and PTEN in 5% of
samples (Figure 5B). Other shared features of LMS were
elevated miR-143 and miR-145 expression, low mRNA expres-
sion of inflammatory response genes, and low leukocyte fraction
by methylation analysis.
In LMS, 12 miRNAs were associated with recurrence-free sur-
vival (RFS) (adjusted p < 0.05; Table S5). The miRNA most highly
associated with RFS was miR-181b-5p (univariate HR 8.03;
adjusted p < 0.0001; Figure S6B). Although high miR-181b
(>571 RPM) was more common in ULMS than in STLMS (26%
versus 6%; p = 0.027), it emerged as an independent predictor
of RFS (HR 7.4, 95% confidence interval 3.1–17.8, p = 9e-6) in
a multivariate model including LMS subtype and tumor size.
miR-181b expression has been reported to promote proliferation
and migration of vascular smooth muscle via the PI3K pathway
(Li et al., 2015); however, we found that high miR-181b-5p was
associated with low expression of its predicted PI3K pathway
targets AKT3 and MTOR (p < 0.006, Wilcoxon test), suggesting
that a different mechanismmay account for the predicted contri-
bution of miR-181b-5p to aggressive behavior in LMS.
Despite their overall similarity and lack of discriminatory
SCNAs, ULMS and STLMS had significantly different methyl-
ation and mRNA expression signatures, with ULMS showing a
higher DNA damage response score (p = 0.005), and hypome-
thylation of ESR1 target genes, while STLMS had a more
prominent HIF1a signaling signature (p = 6e-05) (Figures S6A
and S6C).
iCluster analysis of all LMS defined two distinct clusters, one
highly associated with ULMS and the other with STLMS (Fig-
ure 5B; tumors that were exceptions to clustering by site are
listed in Table S6). Considering STLMS alone, iCluster analysis
defined two subgroups, C1 and C2 (Figure 5C). C1 had worse
recurrence-free survival (RFS; p = 0.0002) and DSS (p = 0.008;
Figure 5D). Our findings are consistent with prior reports of
LMS having 3 mRNA expression subtypes, i.e., a mostly uterine
type and two mostly soft tissue types with very different progno-
ses (Beck et al., 2010; Guo et al., 2015).
The STLMS iCluster groups had molecular features that could
contribute to prognostic differences. Compared with C2, C1 was
hypermethylated and showed higher expression of IGF1R and
factors involved in cell-cycle control (CCNE2), DNA replication
(MCM2), and DNA repair (FANCI) (all with adjusted p % 0.03)
(Table S6). C1 also showed more frequent mutations of RB1
(p = 0.04) and amplification of 17p11.2-p12 (q = 0.022; Fig-
ure S6D), a known alteration in LMS (Pe´rot et al., 2009) that
notably includes MYOCD, encoding myocardin, a transcriptionFigure 5. Leiomyosarcoma
(A) Recurrent focal copy-number alterations in the 80 LMS samples by GISTIC 2.0
amplified and deleted regions.
(B) Molecular landscape of LMS. ULMS was enriched for tumors in iCluster C1, m
STLMS was enriched for the other 2 SCNA clusters: C2 (characterized by chromo
gene mutations were computed by MuSiC2. See also Figure S6 and Table S6.
(C) iCluster analysis of STLMS, demonstrating hypomethylation of C2 relative to C
See also Table S6.
(D) Kaplan-Meier analysis of STLMS iCluster C1 versus C2. Median DSS was 6.7
(E) Recurrent AKT pathway alterations in LMS. Top: pathway diagrams and perce
ULMS and STLMS iClusterC1 and C2. Bottom: specific alterations for each gene
958 Cell 171, 950–965, November 2, 2017factor involved in smooth muscle differentiation. MYOCD was
highly amplified in 13 STLMS and 2 ULMS independent of
tumor site, size, or grade. Both the STLMS C1 cluster and
ULMS were enriched for PTEN deletion, mutation, or downregu-
lation and for amplification or overexpression of AKT pathway
members. Taken together, 46/55 (84%) of ULMS and STLMS
iCluster C1 tumors contained alterations in the AKT pathway
compared to 11/25 (44%) of STLMS iCluster C2 (p = 1e-04; Fig-
ure 5E). The hypomethylated C2 STLMS displayed prominent
signatures of inflammatory cells, including NK cells (p = 0.004)
and mast cells (p = 0.044).
The predicted differences between ULMS and STLMS in
hormonal responsiveness and stress response (e.g., through
HIF1a and DNA damage pathways) support the use of different
management approaches for the two, consistent with current
treatment guidelines (Koh et al., 2015). In LMS as a whole,
aberrant PI3K-AKT-MTOR signaling may be crucial, given
recurrent deletion/mutation of PTEN along with frequent amplifi-
cation and upregulation of IGF1R, AKT, RICTOR, and MTOR
(Figure 5E) and high AKT pathway scores by RPPA. Indeed,
MTOR inhibitors such as everolimus and temsirolimus have
shown some clinical efficacy in LMS (Italiano et al., 2011;
Schwartz et al., 2013), albeit diminished by their indirect upregu-
lation of AKT. Newer TORC1/TORC2 inhibitors and dual PI3K/
MTOR inhibitors may overcome this limitation and offer more
effective therapy for LMS patients.
UPS and MFS: Molecular Data Support a Single Entity
with a Phenotypic Spectrum
Historically, MFS was considered a subset of UPS (‘‘myxoid ma-
lignant fibrous histiocytoma’’), but more recently, MFS and UPS
have been classified as distinct clinical entities based on their
different clinicopathologic features (Fletcher et al., 2013). MFS
has prominent myxoid stroma and is often lower grade and
prone to local relapse, while UPS is generally higher grade,
more cellular, and prone to distant metastasis and shorter
survival.
We found MFS and UPS to be largely indistinguishable across
multiple platforms (Figure 6A), the only exception being a
small cluster within UPS with distinct mRNA, methylation, and
PARADIGM profiles. However, this lack of clear distinction
between MFS and UPS could be explained if our MFS tissues
had underrepresentation of ‘‘classic’’ low-grade MFS areas
and overrepresentation of the high-grade, UPS-like areas that
can evolve within an MFS (Figure S6E). On reviewing the
frozen tissue submitted for TCGA analysis, we found substan-
tial numbers of nonclassic MFS samples (11; 65%) includinganalysis. Green line indicates the significance threshold (FDR 0.25) for focally
RNA C2, methylation C3, and SCNA C3 (characterized by genomic instability).
some 17p1112 gains) and SCNA C1 (genomically quiet). FDR values next to
1. Heatmaps display the most variable distinguishing factors between clusters.
years for C1 and was not reached for C2.
ntage of alterations (mutation, SCNA, and/or relative change in mRNA level) in
.
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Figure 6. Undifferentiated Pleomorphic Sarcoma and Myxofibrosarcoma
(A) Integrated molecular profile of MFS and UPS, showing clusters from unsupervised analyses and recurrent genemutations. FDRs next to genemutations were
computed by MuSiC2.
(B) Molecular classification of UPS/MFS by myxoid stromal content of frozen tumor sample. Unsupervised clustering was performed on genes differentially
expressed (q < 0.05) between groups defined by extent of myxoid stroma (none, 1%–49% of the tissue,R50% of the tissue). ‘‘Classic’’ cases of MFS (n = 6) and
UPS (n = 20) on frozen material are indicated. See also Figure S6E.
(C) SCNAs in MFS and UPS. VGLL3 amplification and RB1 deletion are shown at the top.
(D) Hippo pathway activation. The boxplots show YAP1 and VGLL3 target gene expression signature (He´lias-Rodzewicz et al., 2010).
(E) Multivariable miRNA prognostic classifier for DSS.We performed a penalized regression analysis using all miRNAs and tumor size in the 54UPS/MFS samples
with outcome data. The samples were split into high and low groups based on model score, minimizing the log-rank p value. The p value shown is corrected for
multiple testing.
See also Figure S6F.
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high-grade epithelioid MFS (5; 29%), and these high-grade sam-
ples may have contributed to molecular similarity between MFS
and UPS.
Because the principal morphological distinction betweenMFS
and UPS is the amount of myxoid stroma, we asked whether
genes associated with myxoid stroma could better discriminate
MFS and UPS. We identified genes that were differentially ex-
pressed based on the proportion of histologic myxoid compo-
nent (0, <50%, and R50%). Unsupervised clustering of UPS/
MFS based on this gene set (Figure 6B) segregated MFS from
UPS, whether or not they had classic morphology, with matrix-
associated genes being more highly expressed in MFS. Overall,
our molecular data indicate that these two sarcomas are not
distinct entities, but rather fall along a spectrum, as in the original
nomenclature for these tumors. Thus, cases will be encountered
across a continuum in terms of myxoid component, expression
of matrix-related genes, grade, and clinical behavior. Given the
molecular similarities, common systemic treatment approaches
may be appropriate.
Taking UPS/MFS as a single spectrum of disease, we then
evaluated SCNAs across the combined set of samples (Fig-
ure 6C), finding high-level amplification of CCNE1 in 10%,
VGLL3 in 11%, and YAP1 in 3%, as previously reported (He´l-
ias-Rodzewicz et al., 2010). VGLL3 and YAP1 are TEAD cofac-
tors in the Hippo signaling pathway that induce proliferation.
Copy-number gains of VGLL3 and YAP1 correlated with gene
expression (not shown), and a YAP1/VGLL3 target gene signa-
ture (He´lias-Rodzewicz et al., 2010) was strongly expressed in
UPS/MFS (p = 1e-24; Figure 6D). Thus, a subset of UPS/MFS
may be driven by the Hippo pathway, for which inhibitors are
becoming available.
Multivariable analysis of miRNAs and tumor size in UPS/MFS
identified 7 miRNAs that together with tumor size were associ-
ated with metastasis-free survival (p = 2e-08; Figure S6F), and
7 that together with tumor size were associated with DSS
(p = 3e-6; Figure 6E); both sets of miRNAs included miR-
100-5p and miR-194-5p. Notably, DSS was most strongly
associated with miR-22 downregulation, which has also been re-
ported as a poor prognostic factor in another complex karyotype
sarcoma, osteosarcoma (Wang et al., 2015).
Immune Microenvironment Signatures
Among the variable genes in the pan-sarcoma unsupervised
clustering of the mRNA data were 203 genes involved in im-
mune response and inflammation (Figure 7A). To better define
the immune cell infiltrates, we assigned each sarcoma type
an immune infiltration score for various immune cells based
on their gene expression signatures (Bindea et al., 2013) (Fig-
ure 7B). Cases with high or low immune infiltration scores
typically showed coordinate increases or decreases in multi-
ple inflammatory cell types, rather than changes in a single
cell type.
UPS/MFS and DDPLS had the highest median macrophage
scores among sarcoma types; DDLPS had highest CD8 score,
and STLMS had highest PD-L1 score (Figure S7A), which was
significantly higher than in ULMS (p = 4e-5). Across different tu-
mors, PD-L1 mRNA level correlated with the copy number of its
gene (CD274) (r = 0.42, adjusted p = 4e-10), but not with PD-1960 Cell 171, 950–965, November 2, 2017score. Immune signatures in each sarcoma type were validated
using publically available RNA sequencing (RNA-seq) data from
113 sarcomas (Lesluyes et al., 2016). Median immune signatures
in LMS, MFS, and SS were strongly correlated between the
two studies (Spearman coefficients 0.908, p = 8e-09; 0.819,
p = 9e-06; and 0.858, p = 4e-08, respectively) (Figure S7B).
This approach was not well suited to validation in DDLPS and
UPS (as the immune subtypes all had median scores around
zero in both series), but the distribution of scores was similar be-
tween cohorts (Figure S7C).
We compared DSS of patients with tumors in the top versus
bottom third of immune infiltrate scores (Figure 7C and 7D). NK
cells were the only immune cell type to correlate significantly
with DSS in multiple sarcoma types. For UPS/MFS, DCs and
iDCs correlatedwith improvedDSS, suggesting a role for antigen
presentation in the immunologic response to these tumors. The
impact of immune infiltration scores on DSS differed in STLMS
and ULMS (Figure 7D). In DDLPS, an elevated Th2 signature
was associated with shorter DSS (Figure 7D).
Expression of known druggable immune microenvironment
markers was then assessed. We found differential expression
based on sarcoma type of B7-H3, TGFB1, and TIM3 (p = 1.6e-
15, p = 9.8e-11, and p = 2.9e-14, respectively by Kruskal-Wallis
test; Figure S7D), among other markers, with median expression
highest in DDLPS, UPS, and MFS.
Taken together, these data suggest that the immune microen-
vironment differentially affects outcome in different sarcoma
types, and can contribute positively or negatively to DSS. More-
over, expression of immune microenvironment markers differs
by sarcoma type andmay affect response to immune checkpoint
inhibitors. Such findings are of particular interest given the prom-
ising results of the SARC028 trial of a PD-1 inhibitor, in which
40% of UPS cases showed responses (Burgess et al., 2017).
Our study suggests that these immunotherapy agents should
be specifically explored in MFS as well.
Conclusions
This multi-platform genome-wide dataset provides the most
comprehensive database of DDLPS, MFS, UPS, and LMS
genomic and epigenomic alterations to date. The depth and
breadth of alterations reveals the decidedly heterogeneous na-
ture of adult soft tissue sarcomas and highlights their presumed
dependence on SCNAs, rather than targetable activating point
mutations. In both integrated and platform-specific analyses,
the one fusion-associated sarcoma type in the study (SS) was
the most dissimilar to other sarcomas, but the analyses also re-
vealed distinct differences among LMS and the other complex
karyotype sarcomas. Salient differences include MDM2, CDK4,
JUN, and TERT amplifications in DDLPS;MYOCD amplification,
PTEN mutations/deletions, and AKT, IGF1R, and MTOR
pathway activation in LMS; and VGLL3 amplification and Hippo
pathway activation in UPS/MFS. Across the sarcoma types
(although less so in DDLPS), deletions were more prominent
than amplifications, and relevant mutations in tumor suppres-
sors substantially more frequent than those in oncogenes. More-
over, genomic analyses defined prognostically distinct subsets
of cases among DDLPS and STLMS that could both improve
risk stratification and guide new therapeutic strategies. Immune
AB
C
D
Figure 7. Specific Types of Immune Infiltration Show Associations with Survival Outcomes
(A) Clusters identified by unsupervised clustering of the 2,038 most variably expressed genes across 206 samples. Heatmap shows expression; the gray wedge
marks 203 genes with immune-related and inflammatory-relatedGO terms. The bar graph (right) shows the Benjamini-Hochberg adjusted p values for enrichment
for the specific ontologies listed, as defined by the DAVID algorithm.
(B) Unsupervised cluster analysis of tumors by calculated immune infiltration scores. The analysis defines a subset of DDLPS, LMS, MFS, and UPS with high
immune infiltrates (right).
(C) Selected Kaplan-Meier curves for DSS by histology and immune class. The graphs show the patients in the top third versus bottom third for the immune scores
indicated.
(D) Significant DSS associations (p < 0.05) for high immune score by histology.
See also Figure S7.
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cell infiltration in the tumor microenvironment was commonly
detected in genomically complex DDLPS, LMS, UPS, and MFS
and was highly associated with clinical outcome. Given the
abovementioned efficacy of PD-1 blockade in some UPS, the
nature of the immune cell types recruited may serve as an impor-
tant determinant of response to PD-1 blockade. This study
provides a detailed genomic landscape of multiple sarcoma
types now available for further mining by the sarcoma research
community to improve our understanding of sarcomagenesis,
hopefully leading to new therapeutic approaches for these
deadly diseases.
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RPPA antibodies RPPA Core Facility,
M. D. Anderson Cancer Center;
Gonzalez-Angulo et al., 2011,
PMID:21906370
https://www.mdanderson.org/research/research-
resources/core-facilities/functional-proteomics-
rppa-core/antibody-information-and-protocols.
html See Table S7
Biological Samples
Primary tumor samples Multiple tissue source sites,
processed through the
Biospecimen Core Resource
See Methods: EXPERIMENTAL MODEL AND
SUBJECT DETAILS
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EZ-96 DNA Methylation Kit Zymo Research Cat#D5004
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Preparation Kit
Illumina https://www.illumina.com/techniques/sequencing/
ngs-library-prep.html
Infinium HumanMethylation450
BeadChip Kit
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SeqCap EZ Human Exome 3.0 library Roche Cat#06465692001
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TruSeq RNA library Prep Kit Illumina Cat#RS-122-2001; RS-122-2002
Deposited Data
Raw and processed clinical, array,
and sequence data
NCI Genomic Data Commons https://gdc-portal.nci.nih.gov/legacy-archive/
search/f
Digital Pathology Images NCI Genomic Data Commons
Cancer Digital Slide Archive
https://gdc-portal.nci.nih.gov/legacy-archive/
search/f; http://cancer.digitalslidearchive.net/
Oligonucleotides
120-mer custom capture
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This paper http://genome.wustl.edu/pub/custom_
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cdd7324ce34b49b6834c57ddd89b0e05.bed
120-mer custom capture
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40774c8461274a81b4d223161dc84936.bed
120-mer custom capture
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capture/HPV_IDT_all_pooled_probes/
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120-mer custom capture
oligonucleotides for targeting of TERT promoter
This paper http://genome.wustl.edu/pub/custom_
capture/WO2830729_pooled_probes/
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Software and Algorithms
ABSOLUTE Carter et al., 2012 RRID:SCR_005198; https://www.broadinstitute.
org/cancer/cga/absolute
Array-Pro Analyzer Media Cybernetics
Washington, DC
http://meyerinst.com/imaging-Software/image-
pro/array-pro/index.htm
Bam-readcount v0.4 N/A https://github.com/genome/bam-readcount
Bayesian non-negative matrix
factorization (Bayesian NMF)
Kasar et al., 2015 PMID: 26638776
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Birdseed Korn et al., 2008 RRID:SCR_001122; https://www.broadinstitute.
org/mpg/birdsuite/birdseed.html
Bwa v0.5.9 Li and Durbin, 2009 RRID:SCR_010910; http://bio-bwa.sourceforge.net/
CASAVA Illumina RRID:SCR_001802; https://support.illumina.com/
sequencing/sequencing_software/bcl2fastq-
conversion-software.html
Circular Binary Segmentation (CBS) Olshen et al., 2004 PMID:15475419
ConsensusClusterPlus Wilkerson and Hayes, 2010 http://bioconductor.org/packages/release/bioc/
html/ConsensusClusterPlus.html
ContEst Cibulskis et al., 2011 RRID:SCR_000595; https://www.broadinstitute.
org/cancer/cga/contest
Cutoff Finder Budczies et al., 2012 PMID: 23251644
Cytoscape N/A RRID:SCR_003032; http://www.cytoscape.org
DAVID Huang et al., 2009 RRID:SCR_001881; https://david.abcc.ncifcrf.gov/
Genome Analysis Toolkit (GATK)
v1.0.5336
McKenna et al., 2010 RRID:SCR_001876; https://software.broadinstitute.
org/gatk
GISTIC v2.0.22 Mermel et al., 2011 RRID:SCR_000151; http://www.mmnt.net/db/0/0/
ftp-genome.wi.mit.edu/distribution/GISTIC2.0
Glmnet N/A RRID:SCR_015505 https://cran.r-project.org/
package=glmnet
Heatmap.plus N/A https://CRAN.R-project.org/package=heatmap.plus
iCluster Shen et al., 2009 https://cran.r-project.org/package=iCluster
In Silico Admixture Removal (ISAR) Zack et al., 2013 PMID: 24071852
Indelocator N/A RRID:SCR_005258; https://www.broadinstitute.
org/cancer/cga/indelocator
JoinX v1.9 N/A http://gmt.genome.wustl.edu/packages/joinx/
Mapping Quality Scores (MAQ) Li et al., 2008 RRID:SCR_005485 http://maq.sourceforge.net
MapSlice v0.7.5 Wang et al., 2010 RRID:SCR_010844; http://www.netlab.uky.edu/
p/bioinfo/MapSplice
MatrixEQTL v2.1.1 Shabalin, 2012 https://cran.r-project.org/web/packages/MatrixEQTL/
MClust Yeung et al., 2001 https://cran.r-project.org/package=mclust
MicroVigene VigeneTech RRID:SCR_002820; http://www.vigenetech.com/
microvigeneV3.0.htm
MuSiC2 Dees et al., 2012 https://github.com/ding-lab/MuSic2
MuTect v1.1.6 Cibulskis et al., 2013 RRID:SCR_000559; https://www.broadinstitute.org/
cancer/cga/mutect
MutSig2CV Lawrence et al., 2013 RRID:SCR_010779; http://archive.broadinstitute.org/
cancer/cga/mutsig
Oncotator Ramos et al., 2015 RRID:SCR_005183; https://www.broadinstitute.org/
cancer/cga/oncotator
NMF Gaujoux and Seoighe, 2010 https://cran.r-project.org/package=NMF
OpenOrd Martin et al., 2011 http://www.sandia.gov/smartin/software.html
PARADIGM Sedgewick et al., 2013 http://sbenz.github.io/Paradigm
pHeatmap v1.0.2 N/A https://cran.r-project.org/package=pheatmap
Picard v1.46 N/A RRID:SCR_006525; http://broadinstitute.github.io/
picard/
Pindel v.0.2.2 Ye et al., 2009 RRID:SCR_000560; http://gmt.genome.wustl.edu/
pindel/
RADIA Radenbaugh et al., 2014 https://github.com/aradenbaugh/radia/
RSEM Li and Dewey, 2011 RRID:SCR_013027; http://deweylab.biostat.wisc.
edu/rsem/
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SAMR v2.0 Li and Tibshirani, 2013 https://cran.r-project.org/package=samr
Samtools v0.1.16 Li et al., 2009 RRID:SCR_002105; http://samtools.sourceforge.net
SnpEff Cingolani et al., 2012 RRID:SCR_002105; http://snpeff.sourceforge.net/
SomaticSniper v1.0.4 Larson et al., 2012 RRID:SCR_005108; http://gmt.genome.wustl.edu/
somatic-sniper/current/
Strelka v0.4.6.2 & v1.0.6 Saunders et al., 2012 RRID:SCR_005109; https://sites.google.com/site/
strelkasomaticvariantcaller/home
SuperCurve Hu et al., 2007, Tibes et al., 2006 http://bioinformatics.mdanderson.org/main/
SuperCurve:Overview
Survival N/A https://cran.r-project.org/package=survival
TelSeq Ding et al., 2014 RRID:SCR_002730; https://github.com/zd1/telseq
VarScan v2.2.6 Koboldt et al., 2012 RRID:SCR_006849; http://tvap.genome.wustl.edu/
tools/varscan/
Ziggurat Deconstruction Mermel et al., 2011 PMID: 21527027
Other
Resource website for TCGA
Sarcoma paper
This paper https://tcga-data.nci.nih.gov/docs/publications/
sarc_2017/
Firehose, Firebrowse The Broad Institute,
Cambridge, MA
https://gdac.broadinstitute.org http://firebrowse.org
Regulome Explorer Institute for Systems Biology,
Seattle, WA
http://explorer.cancerregulome.org/
cBioPortal Memorial Sloan Kettering
Cancer Center, New York, NY
RRID:SCR_014555 http://www.cbioportal.org/
TCGA Batch Effects The University of Texas MD
Anderson Cancer Center
http://bioinformatics.mdanderson.org/tcgambatch/CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to andwill be fulfilled by the LeadContact, Alexander
J. Lazar (alazar@mdanderson.org).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human Subjects
TCGA Project Management has collected necessary human subjects documentation to ensure the project complies with 45-CFR-46
(the ‘‘Common Rule’’). The program has obtained documentation from every contributing clinical site to verify that Institutional Re-
view Board (IRB) approval has been obtained to participate in TCGA. Such documented approval may include one or more of the
following:
d An IRB-approved protocol with Informed Consent specific to TCGA or a substantially similar program. In the latter case, if the
protocol was not TCGA-specific, the clinical site PI provided a further finding from the IRB that the already-approved protocol is
sufficient to participate in TCGA.
d A TCGA-specific IRB waiver has been granted.
d A TCGA-specific letter that the IRB considers one of the exemptions in 45-CFR-46 applicable. The two most common exemp-
tions cited were are that the research fall under 46.102(f)(2) or 46.101(b)(4). Both exempt requirements for informed consent
because the received data and material do not contain directly identifiable private information.
d A TCGA-specific letter that the IRB does not consider the use of these data and materials to be human subjects research. The
was most common for collections in which the donors were deceased.
Specimens were collected retrospectively. Selection of adult sarcoma types for the TCGA SARC study was predicated on the abil-
ity to accrue sufficient numbers of cases, and select tumors for which it would be possible to extract high-quality nucleic acids for
analysis. Thus, the study was designed to focus on common adult sarcoma types, including samples from patients diagnosed with
one of the following sarcoma types: dedifferentiated liposarcoma (DDLPS); leiomyosarcoma (LMS) of gynecologic (ULMS) or softe3 Cell 171, 950–965.e1–e16, November 2, 2017
tissue (STLMS) origin; undifferentiated pleomorphic sarcoma (UPS), also known as malignant fibrous histiocytoma (MFH) (pleomor-
phic MFH, giant cell MFH, inflammatory MFH, and UPS not otherwise specified); malignant peripheral nerve sheath tumor (MPNST);
desmoid-type fibromatosis; myxofibrosarcoma (MFS); and synovial sarcoma (SS) (monophasic, biphasic, or poorly differentiated).
Patients were ineligible if they had a history of systemic chemotherapy for sarcoma or if their tumor had undergone prior radiotherapy,
thus adult sarcomas commonly treated with neoadjuvant therapy were not considered for this study. Due to the difficulty in extracting
sufficient DNA and RNA yields, well-differentiated liposarcoma was not considered for inclusion. All tumors were primary, with the
exception of DDLPS, for which recurrent liposarcomas (n = 4) were allowed if the tumor represented the first instance of DDLPS in that
patient.
In total, samples for 437 cases were received at the TCGA Biospecimen Core Resource (BCR), and 206 of them remained in the
study set after QC and Pathology review (see METHOD DETAILS below).
The clinical data collected included patient age, sex, race, ethnicity, height, weight, tumor anatomic location, tumor clinical dimen-
sions, tumor pathology dimensions, clinical and pathologic AJCC staging (7th edition), history of prior cancers, synchronous cancers,
and subsequent cancers (including distant metastasis, local recurrence, or second primary cancers), genetic testing if done, date of
treatments, vital status, date of death, disease-specific survival, recurrence-free survival, and date of last contact. Descriptive clinical
and pathologic data are summarized in Table S1.
Because the selected cases were not consecutive, analyses of association with clinical outcome are considered hypothesis-
generating and require confirmation.
Samples were submitted to the BCR from 32 centers (Analytical Biological Services, Inc.; Baylor College of Medicine (two contrib-
uting sites); Brigham and Women’s Hospital; Cedars-Sinai Medical Center; Christiana Care Health Services, Inc.; Cleveland Clinic;
Cureline, Inc.; Emory University; Fox Chase Cancer Center; Hartford Hospital; Icahn School of Medicine at Mount Sinai; International
Genomics Consortium; ILSbio, LLC; MD Anderson Cancer Center; Memorial Sloan Kettering Cancer Center (two contributing sites);
Moffitt Cancer Center; Montefiore Medical Center; Ontario Institute for Cancer Research (Ottawa); Roswell Park Cancer Institute;
St. Joseph’s Hospital andMedical Center (Phoenix, AZ); University of California, Davis; University of Iowa; University of KansasMed-
ical Center; University of Minnesota; University of New Mexico; University of North Carolina; University of Pittsburgh; University of
Washington; Vanderbilt University; and Washington University) under IRB-approved protocols as described above. Primary tumor
samples and matched germline control DNA (blood or blood components, including DNA extracted at the submitting site; non-
neoplastic solid tissue) were obtained from patients who had received no prior treatment for their disease (chemotherapy or
radiotherapy). Specimens were shipped overnight to the Biospecimen Core Resource using a cryoport that maintained an average
temperature of less than 180C.
High-resolution digital slide images (200x or 400x magnification) were prepared at the BCR, and were taken from both the frozen
section slides created at the BCR from tissue submitted for analysis and representative H&E-stained slides submitted from the tissue
source sites from diagnostic formalin-fixed, paraffin-embedded (FFPE) tumor tissue. In total, one to 6 digital slides were generated
from each case.
METHOD DETAILS
Biospecimens and Quality Control
Frozen section quality control
Frozen sections were assessed for quality, using tumor and normal specimens from a frozen section slide prepared by the BCR. The
percent tumor nuclei, percent necrosis, and other pathology annotations were assessed (see Pathology Review section, below), and
normal samples were confirmed to be free of tumor. Tumor samples withR 60% tumor nuclei and% 20% necrosis were submitted
for nucleic acid extraction.
Sample processing
DNA and RNA were extracted and quality was assessed at the central BCR. RNA and DNA were extracted from tumor using a modi-
fication of the DNA/RNA AllPrep kit (QIAGEN). The flow-through from the QIAGEN DNA column was processed using a mirVana
miRNA Isolation Kit (Ambion). This latter step generated RNA preparations that included RNA < 200 nt suitable for miRNA analysis.
DNA was extracted from blood using the QiaAmp DNA Blood Midi kit (QIAGEN).
RNA samples were quantified by measuring Abs260 with a UV spectrophotometer and DNA quantified by PicoGreen assay. DNA
specimens were resolved by 1% agarose gel electrophoresis to confirm highmolecular weight fragments. A custom Sequenom SNP
panel or the AmpFISTR Identifiler (Applied Biosystems) was utilized to verify, for each case, that tumor DNA and germline DNA were
derived from the same patient. Five hundred nanograms of each tumor and germline DNAwere sent to QIAGEN (Hilden, Germany) for
REPLI-g whole-genome amplification using a 100 mg reaction scale. RNA was analyzed via the RNA6000 Nano assay (Agilent) for
determination of an RNA Integrity Number (RIN), and only analytes with a RINR 7.0 were included in this study. Only cases yielding
a minimum of 6.9 mg of tumor DNA, 5.15 mg RNA, and 4.9 mg of germline DNA were included in this study.
For cases that had sufficient residual tumor tissue following extraction of nucleic acids, a 10- to 20-mg portion of snap-frozen tumor
was submitted to MD Anderson for reverse phase protein array (RPPA) analysis. This portion was adjacent to the tissue used for mo-
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Sample qualification
TheBCR received tumor samples with germline controls from a total of 437 cases, of which 176were disqualified at the BCR. Twenty-
two were disqualified during prescreening at the BCR for not meeting study entry requirements or could not otherwise be processed.
The other 154 disqualified cases did not pass quality control checks at the BCR, including 7 cases for insufficient tumor nuclei
(< 60%), 1 for excessive necrosis (> 20%), 1 for unacceptable diagnosis, 93 for RNA integrity scores of < 7.0, 48 for insufficient nucleic
acid yields, and 4 for not having genotypically matched tumor and germline samples. The 261 cases that qualified were sent for
further genomic analysis. Of these 261 cases, an additional 24 failed further QC during annotation or processing and were removed
from the final cohort, including 4 that failed SNP QC, 5 that failed genotype concordance, 5 that had thousands of putative artifacts,
2 for which mRNA libraries could not be generated, 1 for which miRNA could not be characterized, 4 for history of unacceptable prior
treatment, 2 not meeting study protocol after further annotation, and 1 for which no primary tumor was available. The final set of 237
cases was subjected to further expert pathology review (see below).
Pathology review
A consensus panel of 6 pathologists reviewed and scored the images for 237 sarcomas utilized for molecular analysis after all QC
exclusions. The number of slides available for review from each case ranged from 1-6. Pathology reports were reviewed for tumor
site, depth, reported immunohistochemical studies and/or molecular diagnostics. All cases diagnosed as DDLPS were required to
have evidence of increased chromosome 12q15 copy number, confirmed by copy number analysis. LMS were required to have
unequivocal histologic or immunophenotypic evidence of smooth muscle differentiation.
Consensus review in real-time via screen sharing and conference calls was required for all cases in which expert review was
discrepant from the submitting diagnosis, cases where diagnosis was challenging based on available materials, and for all MFS.
The initial round of consensus reviewed 52 cases. A second round of consensus pathology review occurred to re-evaluate 28 cases
with outlier molecular signatures and confirm consistency of diagnosis of UPS and MFS.
Subsequently all cases of MFS and UPS were re-evaluated by one pathologist and scored for percent myxoid stroma and pres-
ence of classic histologic features on the frozen tissue submitted for molecular analyses. Classic low-grade MFS histology was
defined as having the following features: prominent myxoid stroma with curvilinear vessels, low cellularity, variable nuclear atypia,
and multinodular architecture. Classic UPS was defined as having enlarged, markedly pleomorphic nuclei, a fascicular to storiform
to solid growth pattern, and scant stroma. Cases which had foci of myxoid stroma without characteristic architecture or cellular fea-
tures were not considered to be classic MFS, but were still scored for percent of frozen tumor with myxoid background.
After review, 31 of the 237 caseswere excluded from further analysis (Figures S1A and S4B), including 2 desmoid tumors (excluded
for insufficient number of cases), and 6 tumors of types not included in the study criteria (giant cell tumor of bone, pleomorphic lip-
osarcoma, myxoid liposarcoma, PEComa, atypical intradermal smoothmuscle tumor, and pleomorphic dermal sarcoma). Five cases
were excluded as not being sarcoma, including 3 probable melanomas (Figure S1A). Seventeen cases were excluded as being of
uncertain classification based on available images and reports, and one DDLPS was excluded for being infiltrated by chronic lym-
phocytic lymphoma (CLL). Of the 206 cases considered to represent an acceptable type for study, 20 were re-classified from the
initial diagnosis to a different type, based on histologic appearance, presence or absence of focal chromosome 12q15 amplifica-
tion, and expression of muscle markers (Figure S1A).
Sarcoma grade was calculated using the system of the Fe´de´ration Nationale des Centres de Lutte Contre le Cancer (FNCLCC).
Mitotic counts and percent tumor necrosis were extracted from pathology reports, where available, or estimated on digital images
otherwise. Cases were staged according to the American Joint Committee on Cancer (AJCC) 7th edition staging system.
Copy Number Analysis
SNP-based copy number analysis
Affymetrix SNP 6.0 arrays were used to hybridize genomic DNA from each tumor and normal sample using standard protocols at the
Genome Analysis Platform of the Broad Institute (McCarroll et al., 2008). Briefly, from raw CEL files, Birdseed was used to infer pre-
liminary copy number at each probe locus (Korn et al., 2008). For each tumor, tangent normalization was applied to estimate genome-
wide copy number. Tangent normalization is based on the observation that the linear combination of all normal samples that aremost
similar to the tumor tends to match the noise profile of the tumor better than any set of individual normal samples; this linear com-
bination is therefore used to divide the tumor signals (Cancer Genome Atlas Research Network, 2011) (https://www.broadinstitute.
org/cancer/cga/copynumber_pipeline). Individual copy-number estimates then underwent segmentation using Circular Binary Seg-
mentation (Olshen et al., 2004), during which regions corresponding to germline copy number alterations were removed. Ziggurat
Deconstruction was then applied to assign a length and amplitude to each identified copy number change, in a way that accounts
for different copy number values inferred across the locus from the heterogeneous cell population (Mermel et al., 2011). Allelic copy
number, whole genome doubling, subclonality, purity, and ploidy estimates were calculated using the ABSOLUTE algorithm (Carter
et al., 2012). For samples with ABSOLUTE-corrected copy number, CBS-derived segmented copy number values were re-centered
using the In Silico Admixture Removal (ISAR) procedure (Zack et al., 2013). Significant focal copy number alterations across all sar-
comas andwithin each sarcoma typewere identified from ISAR-corrected segmented data usingGISTIC 2.0.22 (Mermel et al., 2011).
Allelic copy number derived from ABSOLUTE was used along with relative copy number to determine regions of loss of heterozygos-
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Focal amplification & shallow & deep deletion
For each tumor the median copy-ratio for each chromosome arm is calculated. A +2 is calculated as a value that is higher than the
maximumof these arm values. A2 is a value less than theminimumof these values. A +1 or1 (shallow amplifications and deletions
respectively) corresponds to alterations between 0.1 relative copy number and the thresholds for deep alterations (Mermel et al.,
2011). Values of 2 (deep deletion) track with deletions to less than one half the baseline ploidy or homozygous deletions. Values
of +2 represent amplification above chromosome arm–level gains and track with focal amplifications. To validate these definitions,
we compared GISTIC 2.0 calls of shallow or deep deletion or other copy number status for CDKN2A and NF1 with manually curated
ABSOLUTE calls for homozygous or heterozygous deletion or other copy number status. For each gene, there was significant cor-
relation between deep deletion and homozygous deletion, shallow deletion and heterozygous deletion, and ‘‘other’’ categories, chi-
square p < 0.0001.
Copy number–based cluster analysis
Tumors were clustered based on thresholded copy number at recurring alteration peaks from GISTIC analysis (all_lesions.
conf_99.txt file). Clustering was done in R based on Manhattan distance using Ward’s method.
Assessment of ATRX copy number alterations
The copy number alteration (more specifically deletion) of ATRXwas assessed independently using twomethods, SNP6.0 arrays (see
SNP-based copy number analysis, above) and VarScan 2 (Koboldt et al., 2012). In VarScan 2, the tumor and its matching normal
whole-exome BAM files were assessed simultaneously using a heuristic approach to detect sequence variants. Copy number
changes were assigned after normalization of read depths of the two BAM files. The copy number alteration was validated by
comparing the outputs of both methods while taking into consideration the purity of the samples. A sample was considered to
have copy number deletion in ATRX when the outputs from both methods gave < 1.79 in the locus or part of the locus and when
GISTIC2.0 indicated a deletion status.
DNA Sequencing and Analysis
Whole exome and whole genome sequencing
Whole exome sequencing and, in a subset of cases, whole genome sequencing were performed at Washington University. Dual-
indexed Illumina libraries were constructed according to standard protocols. Unique, 6bp molecular barcodes were used to identify
individual samples. Exome capture enrichment was performed with pooled libraries using Nimblegen SeqCap EZ Human Exome
v3.0. Samples were subsequently sequenced on Illumina HiSeq 2000 instruments. The pool size varied, but was generally 8-10.
Each pool was sequenced across 2 lanes. A total of 518 tumor and normal aliquots from 255 cases were sequenced to a minimum
average target depth of 20x across 80% of target regions. The 206 cases in the final cohort were utilized for downstream analysis.
40 exome-sequenced cases were selected for additional whole genome sequencing (WGS) and 37 were retained for downstream
analysis (18 DDLPS, 8 STLMS, 10 ULMS, and one UPS). WGS was performed using Illumina HiSeq 2000 for the initial 70 aliquots
and HiSeq X Ten instrument for the final 13 aliquots.
Validation of somatic mutations
A second set of dual-indexed Illumina libraries was constructed according to standard protocols using the original DNA aliquots
when sufficient genomic DNAwas available (n = 197 samples). These were pooled, then enriched by performing hybrid capture using
120-mer custom capture oligos (Integrated DNA Technologies [IDT]). The target regions for somatic indels and point mutations were
defined as a 100-bp region surrounding the mutation site. For probes designed in repetitive regions, those having > 5 mismatches to
similar sequences in the human genome were discarded. Sequence data were generated on Illumina HiSeq 2500 instruments.
Among the 197 samples with custom capture validation data from the second library, 90.8% (9557/10522) of reported mutations
were confirmed.
In order to identify TERT promoter mutations and presence of cancer –related viruses, original source material from the second
set of libraries was also pooled and hybridized to 120-mer IDT probes targeting the TERT promoter mutation hotspots and can-
cer-related viruses. Sequence data for the TERT promoter and cancer-related viruses were generated using Illumina MiSeq
instruments.
Target and probe bed files for all capture sets were submitted to CGHub and are available at http://genome.wustl.edu/pub/
custom_capture/.
Read alignment
Each lane or sub-lane of data for whole genome, exome and custom capture validation sequencing was aligned with bwa v0.5.9 (Li
and Durbin, 2009) to GRCh37-lite. Defaults were used in both bwa aln and bwa sampe (or bwa samse if appropriate) with the excep-
tion that for bwa aln we used four threads (-t 4) and bwa’s built in quality-based read trimming (-q 5). ReadGroup entries were added
to resulting SAM files using Samtools add-read-group-tag. This SAM file was then converted to a BAM file using Samtools v0.1.16,
name sorted (samtools sort -n), mate pairings assigned (samtoolsfixmate), resorted by position (samtools sort), and indexed using
Samtools index-bam.
Read duplication marking and merging
Reads from multiple lanes, but the same sequencing library, were merged, if necessary, using Picard v1.46 MergeSamFiles and
duplicates were then marked per library using Picard MarkDuplicates v1.46. Lastly, each per-library BAM with duplicates marked
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and MERGE_SEQUENCE_DICTIONARIES = true parameters. For both tools, ASSUME_SORTED = true and VALIDATION_
STRINGENCY = SILENTwere specified. All other parameters were set to defaults. Samtoolsflagstat was run on each BAM file gener-
ated (per-lane, per-library, and final merged).
Multicenter mutation calling
Mutations were called by four production or analysis centers within the TCGA network; Washington University, Broad Institute, UC
Santa Cruz (UCSC), and Canada’s Michael Smith Genome Sciences Centre, BC Cancer Agency (BCGSC). Filtered calls from the
4 callers utilized by Washington University (described below) were merged using joinx v1.9 (joinx sort --unique --stable). Germline
dbSNP sites reported by the 1000 Genomes Projects were filtered if the minor allele fraction was greater than zero. In addition,
for the normal BAM,we removed putative variants with fewer than 8x coverage of the reference allele or greater than 1 somatic variant
supporting read or 1% variant allele frequency. For the tumor exome BAM, we required a minimum of 2 supporting read and a so-
matic variant allele frequency of 5%. Additional novel somatic mutation calls submitted by the Broad Institute, BCGSC, and UCSC to
the TCGA Data Coordinating Center were downloaded and filtered to remove known, common germline dbSNP sites. Remaining
variants were annotated using Gencode 19 transcripts from Ensembl release 74, and non-coding sites were removed. Read counts
were generated for all remaining novel putative variants, and said variants were incorporated into the final mutation annotation format
(MAF) if they met the same minimum coverage, maximum coverage, and variant allele frequency requirements described below.
A separate MAF was delivered for the somatic mutations called in whole-genome sequence data; it used the same alignment and
detection parameters described for exome analysis with no restriction for coverage or protein translational effect.
Single-nucleotide variant and indel callers
Single-nucleotide variant (SNV) calling and analytic pipelines were performed as follows in an institution-specific manner:
Washington University: Single-nucleotide variant (SNV) callers included: Samtools v0.1.16 (Li et al., 2009) (samtools pileup
--cv -A -B), SomaticSniper v1.0.4 (Larson et al., 2012) (bam-somaticsniper -F vcf -G -L -q 1 -Q 15), Strelka v0.4.6.2 (Saunders
et al., 2012) (with default parameters except for setting is SkipDepthFilters = 1), and VarScan v2.2.6 (Koboldt et al., 2012) (--min-
coverage 3 --min-var-freq 0.08 --p value 0.10 --somatic-p value 0.05 --strand-filter 1).
TheWashington University analytic strategy was as follows: First, Samtools calls were retained if they met all of the following rules,
inspired by themapping short DNA sequencing reads and calling variants using themapping quality scores (MAQ) software algorithm
(Li et al., 2008):
d Site is greater than 10 bp from a predicted indel of quality 50 or greater
d The maximum mapping quality at the site isR 40
d Fewer than 3 SNV calls in a 10 bp window around the site
d Site is covered by at least 3 reads and fewer than 1,000,000,000 reads
d Consensus qualityR 20
d SNP qualityR 20
After these filters were applied, Samtools and SomaticSniper calls were unioned using joinx v1.9 (https://github.com/genome/
joinx; joinx sort --stable --unique). The resulting merged set of variants were additionally filtered to remove likely false positives (Lar-
son et al., 2012; Li et al., 2009). Bam-readcount v0.4 (https://github.com/genome/bam-readcount) with aminimum base quality of 15
(-b 15) was used to generate metrics, and sites were retained based on the following requirements:
d Minimum variant base frequency at the site of 5%
d Percent of reads supporting the variant on the plus strandR 1% and% 99% (variants failing these criteria are filtered only if the
reads supporting the reference do not show a similar bias)
d Minimum variant base count of 4
d Variant falls within the middle 90% of the aligned portion of the read
d Maximum difference between the quality sum of mismatching bases in reads supporting the variant and reads supporting the
reference of 50
d Maximum mapping quality difference between reads supporting the variant and reads supporting the reference of 30
d Maximumdifference in aligned read length between reads supporting the variant base and reads supporting the reference base
of 25
d Minimum average distance to the effective 30 end of the read for variant supporting reads of 20% of the sequenced read length
d Maximum length of a flanking homopolymer run of the variant base of 5
After this filtering, the SomaticSniper/Samtools calls were additionally filtered to high confidence variants by retaining only those
sites where:
d The average mapping quality of reads supporting the variant allele wasR 40
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VarScan calls were retained if they met the following criteria:
d VarScan reported a somatic p value% 0.07
d VarScan reported a normal frequency% 5%
d VarScan reported a tumor frequencyR 10%
d VarScan reportedR 2 reads supporting the variant.
VarScan variants passing these criteria were then filtered for likely false positives using bam-readcount v0.4 and identical criteria as
described above for SomaticSniper. Fully filtered calls as described above for SomaticSniper and VarScan were then merged with
calls from Strelka using joinx v1.9 (joinx sort --stable --unique) to generate the final callset.
Indels were detected using four methods: Genome Analysis Toolkit (GATK) 1.0.5336 (McKenna et al., 2010) (-T IndelGenotyperV2
--somatic --window_size 300 -et NO_ET), retaining only those which were called as somatic; Pindel v0.2.2 (Ye et al., 2009) (-w 10;
with a config file generated to pass both tumor and normal BAM files set to an insert size of 400); Strelka v0.4.6.2 (with default
parameters except for setting isSkipDepthFilters = 1); and VarScan v2.2.6 (--min-coverage 3 --min-var-freq 0.08–p value
0.10 --somatic-p value 0.05 --strand-filter 1).
Pindel calls were retained if:
d They had no support in the normal data
d More reads were reported by Pindel than reported by Samtools at the indel position or if the number of supporting reads from
Pindel wasR 8% of the total depth at the position reported by Samtools
d Samtools reported a depth less than 10 at the region and Pindel reported more indel supporting reads than reads mapped with
gaps at the site of the call
d A Fisher’s exact test p value% 0.15 was returned when comparing the normal to the tumor in number of reads with gapped
alignments versus reads without.
VarScan indel calls were retained if VarScan reported all of the following:
d A somatic p value% 0.07
d A normal frequency% 5%
d A tumor frequencyR 10%
d R 2 reads supporting the variant.
Broad Institute: To avoid mix-ups between tumor and normal samples, as well as cross-contamination between tumor samples,
alignments were first subjected to quality control using ContEst (Cibulskis et al., 2011). TheMuTect algorithm version 1.1.6 (Cibulskis
et al., 2013) was used to generate somatic mutation calls, which were subsequently filtered as previously described (Costello et al.,
2013) to remove any spurious calls due to shearing-induced generation of 8-oxoguanine. Indels were identified using the indelocator
algorithm. Details and tools are available at https://www.broadinstitute.org/cancer/cga. Functional annotation of mutations was per-
formed with Oncotator (Ramos et al., 2015) using Gencode V18.
UCSC: Single-nucleotide somatic mutations were identified by RADIA (RNA AND DNA Integrated Analysis), a method that com-
bines the patient-matched normal and tumor DNA whole exome sequencing (WES) with the tumor RNA sequencing (RNA-Seq) for
somatic mutation detection (Radenbaugh et al., 2014), software available at: https://github.com/aradenbaugh/radia/. The inclusion
of the RNA-Seq data in RADIA increases the power to detect somatic mutations, especially at low DNA allelic frequencies. By inte-
grating the DNA and RNA, we can rescue some mutations that would be missed by traditional mutation calling algorithms that
examine only the DNA. RADIA classifies somatic mutations into 3 categories depending on the read support from the DNA and
RNA: 1) DNA calls – mutations that had high support in the DNA, 2) RNA Confirmation calls – mutations that had high support in
both the DNA and RNA, 3) RNA Rescue calls – mutations that had high support in the RNA and weak support in the DNA. Here RADIA
identified 32,573 DNA mutations, 5,785 RNA Confirmation mutations, and 843 RNA Rescue mutations.
BCGSC: Strelka (Saunders et al., 2012) (v1.0.6) was used to identify somatic single-nucleotide variants and short insertions and
deletions from the TCGASARC exome dataset. All parameters were set to defaults, with the exception of ‘‘isSkipDepthFilters,’’ which
was set to 1 in order to skip depth filtration, given the higher coverage in exome datasets. We analyzed 259 pairs of libraries. When a
blood sample was available, it served as the matched normal specimen; otherwise, the matched normal tissue was used. The var-
iants were subsequently annotated using SnpEff (Cingolani et al., 2012), and the COSMIC (v61) (Forbes et al., 2010) and dbSNP
(v137) (Smigielski et al., 2000) databases.
Identification of significantly mutated genes
The entire set of 206 sarcomas and those sarcoma typeswith greater than 15 samples (LMS, DDLPS, UPS, andMFS) were separately
analyzed for significantly mutated gene (SMG) detection. Variants from theMAF (described previously) were used to define the region
of interest (ROI) file. Coverage for each sample over an ROI was collected using the corresponding tumor/normal bam file. MAF files
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analysis. We performed MuSiC2 (https://github.com/ding-lab/MuSiC2) frequency-based SMG identification (Dees et al., 2012).
SMGs were defined as genes significantly mutated with FDR < 0.05 using a convolutions test.
Identification of driver mutations
Due to the smaller sample sizes per cohort and the lower mutation frequency of somatic point mutations and indels in sarcoma, we
expanded our analysis to identify additional mutations in putative cancer genes. A collection of 624 cancer genes (Niu et al., 2016)
was used to identify possible driver mutations in individual cases.
Assessment of telomere length
Sequencing reads containing (TTAGGG)7 repeats were classified as telomeric based on previously reported results (Ding et al., 2014),
and TelSeq was used to estimate the telomere length (Ding et al., 2014). The telomeric reads were quantified, and the telomere
lengths of tumor and its matching normal were estimated separately as a function of sequencing depth. Reliability of telomeric con-
tent estimated from WES was confirmed by high concordance with telomeric length inferred from 31 cases with available and
compatible whole-genome sequencing (WGS) files (Pearson correlation: 0.79). To validate TelSeq results, we also assessed telomere
length from exome data by an independent method (written in-house). The outputs from both TelSeq and the in-house method were
log2 transformed and subsequently compared. The results were in high concordance with each other (Pearson correlation = 0.98).
To assess telomere length in the sarcomas, we performed a Gaussian Mixture Clustering guided by optimal Bayesian information
criterion value on the log2 ratio of tumor telomere length usingmclust package in R (Yeung et al., 2001). Based on the clustering result,
we identified three groups: 1) samples with gain in telomere length, 2) samples with loss in telomere length, and 3) samples with no
change in telomere length.
The association of ATRX, PRKDC, and TP53mutations/deletions with telomere length of different sarcoma subtypeswas assessed
with Student’s t tests. Multiple regression analysis was also performed to look for association of several differentially expressed
genes with changes in telomere length. Variables included in the multiple regression analysis were: ATRX mutation/deletion status,
TP53 mutation status, and expression levels of ATRX, TP53, HNRNPC, APEX1, NPM1, RPS17, and SEC11C.
Mutation Signature Analysis
De-novo signature discovery in WES samples
To systematically explore mutational processes operating in 205 SARC WES samples (excluding one sample, AB2E, with ultraviolet
signature), we first performed a de-novo signature extraction using a Bayesian variant of the non-negative matrix factorization
(Bayesian NMF) (Kasar et al., 2015).
De-novo signature discovery in WGS samples
The lack of power due to a low mutation rate in WES samples (57 mutations per tumor) was a significant challenge in the de-novo
signature discovery. Therefore, we performed a separate signature discovery in 37 WGS samples (5010 mutations per tumor) to
examine additional processes that had only a minor contribution in WES. The resulting WGS signatures were then projected onto
coding regions to distinguish mutational signatures similar to either those observed in WES samples or novel signatures.
Inference of signature activity
De-novo signature discovery in both WES and WGS samples identified four major mutational processes: COSMIC1, spontaneous
cytosine deamination; COSMIC5, unknown etiology; COSMIC6, microsatellite instability (MSI); and COSMIC2/13, APOBEC. Based
on this de-novo signature analysis we performed a projection approach to infer sample-specific activities of those mutational pro-
cesses. We first removed two putative MSI samples to minimize possible contamination and interference among signatures, and
we utilized a variant of NMF to enable a forced de-convolution of mutational processes in 203 WES samples. More specifically,
the projection was done by minimizing the Kulbeck-Leibler divergence while we froze the signature-loading matrix, W (96 3 4),
comprised of the column vectors corresponding to normalized signature profiles of COSMIC1, COSMIC5, and COSMIC2 and 13,
and while we iteratively updated the activity-loading matrix H (4 3 203) to best approximate the mutation count matrix, X (96 3
203). The resulting row vectors in H represents a de-convoluted signature activity across samples (Figure 3A). We validated the ac-
curacy of the projection approach by examining the correlation between (1) the inferred activity of COSMIC2 and 13 (APOBEC) in
WES samples determined from the projection approach and (2) the combined activity of SIG.WGS.2 and SIG.WGS.4 determined
from the de-novo signature discovery for 37 WGS samples (Pearson correlation = 0.7 and p < 106).
mRNA Analysis
mRNA library construction and processing
One mg of total RNA was converted to mRNA libraries using the Illumina mRNA TruSeq kit (RS-122-2001 or RS-122-2002) following
the manufacturer’s directions. Libraries were sequenced 48x7x48 bp on the Illumina HiSeq 2000 as previously described (Cancer
Genome Atlas Research Network, 2012). FASTQ files were generated by CASAVA. RNA reads were aligned to the hg19 genome as-
sembly using MapSplice 0.7.5 (Wang et al., 2010). Gene expression was quantified for the transcript models corresponding to the
TCGA GAF2.1 (https://gdc-api.nci.nih.gov/v0/data/a0bb9765-3f03-485b-839d-7dce4a9bcfeb) using RSEM (Li and Dewey, 2011),
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Fusion gene alignments were determined using MapSplice (Wang et al., 2010). For further details on this procedure, refer to
Description file at the Genomic Data Commons (GDC) data portal under the V2_MapSpliceRSEM workflow (https://gdc-api.nci.
nih.gov/legacy/data/e34a93ee-d3c4-44c7-8bfa-0c19c6df0866). Putative TRIO fusions were selected from discordant paired end
reads in which the non-TRIO end mapped to an identified gene. BAM files and expression data can be found at the Genomic
Data Commons (https://gdc-portal.nci.nih.gov/legacy-archive/search/f).
mRNA expression–based cluster analysis
To understand the mRNA abundance relationships between tumors, we performed hierarchical clustering on variable genes. Genes
were first filtered by removing all genes that had < 90% expression data greater than zero across all tumors. Expression values were
log2-transformed, followed by median centering for each gene across all tumors and for all genes within each tumor, respectively.
Genes were further filtered to 2,038 by selecting genes with a standard deviation across all tumors R 2. These genes were used
for clustering using ConsensusClusterPlus on R (v2.12.2) with 1,000 permutations (Wilkerson and Hayes, 2010). Options included
maxK = 10, pItem = 1, pFeature = 0.9, clusterAlg = ’’hc,’’ distance = ’’pearson,’’ and a seed value of 123.456. Clusters were selected
based on the change in area under the cumulative distribution function curve, with the number of clusters selected being the mini-
mum value that would capture most of the information. Gene ontologies were generated using DAVID (Huang et al., 2009).
Calculation of immune infiltration score
Immune infiltration scores were based on the gene groups previously identified (Bindea et al., 2013). To determine an immune infil-
tration score for each tumor, the mRNA abundances scored for genes that comprised each group were first individually median-
centered across all tumors. Second, for each tumor, the median-centered values of every gene within an immune class were
averaged together to yield the reported scores. Survival curves were generated by taking cases representing the top and bottom
33% of scores in each immune class for each histology and plotting disease-specific survival using in-house scripts.
Validation of immune infiltration scores
In order to validate the sarcoma-specific immune infiltration scores identified in our cohort, we repeated our analysis using RNA-seq
data from a publically available dataset including 42 UPS, 36 LMS, 18 DDLPS, 15 MFS, and 2 SS (Lesluyes et al., 2016). Only fresh
frozen tissue samples were included in the analysis. As with our cohort, median immune infiltration scores were calculated for each of
the 24 immune signatures across all sarcoma histologies. For each sarcoma type, a scatterplot was generated where the median
immune infiltration score for each immune signature served as the x- or y- axis for our data and the Lesluyes et al. (2016) data, respec-
tively, and the Spearman correlation coefficient was calculated.
Correlation of UPS/MFS morphology with mRNA
Percent myxoid component (described above in Pathology Review) was used to group UPS andMFS samples into three classes: no
myxoid stroma (class 0), 1%–49% myxoid stroma (class 1), or 50%–100% myxoid stroma (class 2). A multiclass analysis (Tusher
et al., 2001) was performed to identify differentially expressed genes between the classes; this identified 589 genes with a q value <
0.05. These differentially expressed genes were then used to perform unsupervised cluster analysis of all of the UPS/MFS tumors.
HIF1a target gene expression signature
HIF1a target gene expression signature in LMS was calculated as the negative mean expression of genes downregulated by HIF1A
knockdown minus the mean expression of genes upregulated by HIF1A knockdown (Elvidge et al., 2006).
Yap1/ VGLL3 target gene expression signature
Yap1/VGLL3 target gene signature in UPS/MFS was calculated as the difference in median expression of up- and down- regulated
genes (He´lias-Rodzewicz et al., 2010).
Sarcoma tumor map
A tumor map was constructed from the mRNA expression results for the soft tissue sarcomas. The Tumor Map represents a dimen-
sionality reduction and visualization method for high-dimensional data. It allows viewing and browsing relationships between high-
dimensional heterogeneous samples in a two-dimensional map, analogous to exploring geographical maps in the Google Maps web
application. Samples were arranged in a two-dimensional space and then associated to hexagons in a regular hexagonal grid. The
relative distances in themap approximated the relative similarities between the samples in the original high-dimensional space. Sam-
ples found to have similar profiles were placed near each other in the map. Samples that were less similar were placed farther away
from each other. Given that such relations are preserved, clusters of samples that appear as ‘‘islands’’ in the map indicate groups of
samples that share expression features.
To build the sarcomamap (Figure S4B), we usedmRNA expression RNA-Seq data for 259 samples: the 206 in the final analysis; the
22 cases with mRNA expression data which had been sent for genomic analysis but failed QC during annotation; and the 31 cases
excluded in pathology review (Figure S1A).We computed pairwise Spearman correlation for each pair of mRNA expression profiles in
the sarcoma cohort to obtain a pairwise similarity matrix (259 samples by 259 samples). To build the map layout, the closest neigh-
borhood of 6 samples was selected for each sample from the similarity matrix. We represented the local neighborhoods as a sparse
graph where the nodes are the samples, and an edge links any two samples if one of them is among the top 6 neighbors of the other.
The magnitude of the similarity was used as the edge weight. An X-Y position in the two-dimensional plane was calculated from the
graph using a spring-embedded graph layout algorithm implemented in the OpenOrd (formerly DrL) toolbox (Martin et al., 2011). The
spring-embedded layout algorithm treated edges as springs and allowed the springs to oscillate for a fixed amount of time with
the energy inversely proportional to the edge weights. Under these conditions, springs with large weights do not oscillate much,
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This method allowed the construction of a two-dimensional spatial layout of the graph with clusters of samples forming clique-like
hub sub-structures. Our method then associated each of the nodes with a fixed location on a two-dimensional hexagonal grid. Each
hexagon-shaped cell in the grid was assigned no more than one vertex, and some were assigned none, representing ‘‘empty space’’
in the map. If multiple vertices contested for the same grid cell, a random vertex selection was made and placed into the cell; and the
other competing vertices were assigned to neighboring empty cells using a greedy strategy, snapping around the original cell in a
spiral-like manner.
miRNA Analysis
MicroRNA libraries and sequencing
We generated microRNA sequence (miRNA-seq) data using methods described previously (Chu et al., 2016). Briefly, reads were
aligned to the GRCh37/hg19 reference human genome, and read count abundance was annotated with miRBase v16 stemloops
and mature strands. While the read counts included only exact-match read alignments, .bam files at CGHub (http://cghub.ucsc.
edu) (Wilks et al., 2014) included all sequence reads.We usedmiRBase v20 to assign 5p and 3pmature strand (miR) names toMIMAT
accession IDs.
Cluster analysis of miRNA mature strands
To identify subtypes within the various sarcoma cohorts, we used unsupervised hierarchical clustering with pheatmap v1.0.2 in R.
The input was a reads-per-million (RPM) data matrix for the 303 (top 25%) miRBase v16 5p or 3p mature strands that had the largest
variances across the cohort. We transformed each row of the matrix by log10(RPM + 1), then used pheatmap to scale the rows. We
usedWard.D2 for the clustering method with Pearson correlation and Euclidean as the distancemeasures for clustering the columns
and rows, respectively.
We first conducted this analysis on the full pan-sarcoma set and found that the LMS samples drove the top most variable miRNAs
and in turn, the clustering solution (Figure S3C). In order to better identify subtypes within the nonLMS samples, we chose the top
25% most variable miRs within the nonLMS set and reclustered using only these nonLMS samples.
Differentially abundant microRNAs
We identified miRs that were differentially abundant using unpaired two-class SAM analyses (samr v2.0) (Li and Tibshirani, 2013) with
an RPM input matrix and a false discovery rate (FDR) threshold of 0.05.
miR targeting
We assessed potential miRNA-gene targeting for all tumor samples by calculating miR-mRNA Spearman correlations with
MatrixEQTL v2.1.1 (Shabalin, 2012), using gene-level normalized abundance RNA-seq (RSEM) data. We calculated correlations
with a P value threshold of 0.05, then filtered the anticorrelations at FDR < 0.05. We extracted miR-gene pairs that corresponded
to functional validation publications (luciferase reporter, qPCR, western blot) reported by miRTarBase V6.0 (Hsu et al., 2014).
Prognostic miRNAs
We identified miRs that were associated with relapse-free survival (RFS), metastasis-free (MFS) and disease-specific survival (DSS)
in UPS/MFS, DDLPS, and LMS sample sets. To do this, we used Cutoff Finder to determine, for each miR with mean > 50 RPM, the
optimal expression value that would stratify samples into the two groups with the smallest Kaplan-Meier log-rank p value (Budczies
et al., 2012). We adjusted the p values for maximal selection based on formula 1 (Faraggi and Simon, 1996; Gaujoux and Seoighe,
2010), and then adjusted those p values using Benjamini-Hochberg multiple testing correction.
As a complementary analysis we createdmultivariable models which incorporated several miRNAs, aswell as tumor size, to further
refine prognostication. Specifically, we used a LASSO penalized regression approach (R package: glmnet; family = cox; alpha = 1) to
identify sets of miRs and coefficients that together would best predict RFS and DSS in each of the histology types. Once each sample
was assigned a score based on the linear model, we ran cutoff finder to determine the optimal segregation of groups and applied the
same maximal selection correction to the minimum log-rank p value as above.
Within LMS, miRNA-181b, tumor size, and site (ULMS versus STLMS) were analyzed as predictors of RFS in a multivariable Cox
regression model using the coxph function from the survival package in R. miR-181b expression was dichotomized at the cutoff
defined by Cutoff Finder as described above. Tumor size was dichotomized at the median.
DNA Methylation Analysis
Sample preparation and hybridization
The Illumina Infinium HM450 array (Bibikova et al., 2011) was used to assay the 206 TCGA sarcoma samples using standard proto-
cols. Briefly, genomic DNA (1 mg) for each sample was treated with sodium bisulfite, recovered using the Zymo EZ DNA methylation
kit (Zymo Research, Irvine, CA) according to the manufacturer’s specifications, and eluted in 18 ml volume. After passing quality con-
trol, bisulfite-converted DNA samples were whole-genome amplified, fragmented enzymatically, hybridized overnight to BeadChips,
then subjected to locus-specific base extension with labeled nucleotides (Cy3 and Cy5). BeadArrays were scanned and the raw data
imported into custom programs in R computing language for pre-processing and calculation of DNAmethylation beta value for each
probe and sample. Quality control and probe exclusions were done using standard protocols as previously described (Cancer
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DNA methylation based cluster analysis
We carried out an unsupervised consensus clustering as implemented in the Bioconductor package ConsensusClusterPlus, with
Euclidean distance and partitioning around medoids (PAM). Consensus clustering was applied to the DNA methylation data from
the entire cohort, using the most variable 1% of CpG probes. DNA methylation–based subtypes were identified using a robust
5-group partition of the samples obtained using themost variable CpG loci on the Illumina InfiniumHM450 array (Figure S3B). Fisher’s
exact test was used to test for associations of methylation clusters with mRNA expression clusters and significantly mutated genes.
Estimation of leukocyte fraction
We estimated leukocyte fraction in each tumor by calculating the leukocyte signature from methylation results as described (Carter
et al., 2012). As a source of leukocytemethylation level, we usedDNAmethylation data of peripheral bloodmononuclear cells (PBMC)
from six healthy donors (Reinius et al., 2012) (GEO: GSE35069).
RPPA analysis
RPPA experiments and data processing
Protein was extracted from frozen tumor tissue using RPPA lysis buffer (1% Triton X-100, 50 mmol/L HEPES (pH 7.4), 150 mmol/L
NaCl, 1.5mmol/LMgCl2, 1mmol/L EGTA, 100mmol/L NaF, 10mmol/L NaPPi, 10%glycerol, 1mmol/L phenylmethylsulfonyl fluoride,
1 mmol/L Na3VO4, and 10 mg/mL aprotinin) and Precellys homogenization. RPPA was performed as described previously (Hu et al.,
2007; Tibes et al., 2006). Tumor lysates were adjusted to 1 mg/mL concentration as assessed by bicinchoninic acid assay and boiled
with 1% SDS. Tumor lysates were manually serially diluted five times, each a two-fold dilution in lysis buffer. An Aushon Biosystems
2470 arrayer (Burlington, MA) printed 1,056 samples on nitrocellulose-coated slides (Grace Bio-Labs). Slides were probed with 192
validated primary antibodies (Table S7) followed by corresponding secondary antibodies (goat anti-rabbit IgG, goat anti-mouse IgG,
or rabbit anti-goat IgG). Signal was captured using a Dako Cytomation-catalyzed system and DAB colorimetric reaction. Slides were
scanned in a CanoScan 9000F. Spot intensities were analyzed and quantified using Array-Pro Analyzer (Media Cybernetics Wash-
ington DC) to generate spot signal intensities (Level 1 data). The software SuperCurveGUI (Hu et al., 2007), available at http://
bioinformatics.mdanderson.org/Software/supercurve/, was used to estimate the EC50 values of the proteins in each dilution series
(in log2 scale). Briefly, a fitted curve (‘‘supercurve’’) was plotted with the signal intensities on the y axis and the relative log2 concen-
tration of each protein on the x axis using the non-parametric, monotone increasing B-spline model (Tibes et al., 2006). During the
process, the raw spot intensity datawere adjusted to correct spatial bias beforemodel fitting. AQCmetric was returned for each slide
to help determine the quality of the slide: if the score was less than 0.8 on a 0-1 scale, the slide was dropped. In most cases, the
staining was repeated to obtain a high-quality score. If more than one slide was stained for an antibody, the slide with the highest
QC score was used for analysis (Level 2 data). Protein measurements were corrected for loading as described (Gonzalez-Angulo
et al., 2011; Hu et al., 2007) using median centering across antibodies (Level 3 data). The analysis included 192 antibodies and
173 sarcoma samples: 46 DDLPS, 60 LMS, 5 MPNST, 15 MFS, 6 SS, and 41 UPS. Final selection of antibodies was also driven
by the availability of high-quality antibodies that consistently pass a strict validation process as previously described (Hennessy
et al., 2010). These antibodies were assessed for specificity, quantification, and sensitivity (dynamic range) in their application for
protein extracts from cultured cells or tumor tissue. Antibodies were labeled as validated and used with caution based on the degree
of validation by criteria previously described (Hennessy et al., 2010).
RPPA arrays were quantitated and processed (including normalization and load controlling) as described previously, using
MicroVigene (VigeneTech, Inc., Carlisle, MA) and the R package SuperCurve (version-1.3), available at http://bioinformatics.
mdanderson.org/main/SuperCurve:Overview (Hu et al., 2007; Tibes et al., 2006). Raw data (level 1), SuperCurve nonparametric
model fitting on a single array (level 2), and loading-corrected data (level 3) were deposited at the GDC.
Data normalization
We performed median centering across all the antibodies for each sample to correct for sample loading differences. Those differ-
ences arise because protein concentrations are not uniformly distributed per unit volume. That may be due to several factors,
such as differences in protein concentrations of large and small cells, differences in the amount of proteins per cell, or heterogeneity
of the cells comprising the samples. By observing the expression levels across many different proteins in a sample, we can estimate
differences in the total amount of protein in that sample versus other samples. Subtracting themedian protein expression level forces
the median value to become zero, allowing us to compare protein expressions across samples.
RPPA consensus clustering
173 samples (Figure S4C) with RPPA data were assessed. Pearson correlation was used as distance metric andWard’s method was
used as a linkage algorithm in the clustering analysis. We identified five robust sample clusters, with most of the LMS samples clus-
tering together in Cluster1 and the other histologic types being distributed between the rest of the clusters. The clusters and their
protein expression patterns can be viewed through the next-generation clustered heatmap (NGCHM) pipeline developed at the Uni-
versity of Texas MD Anderson Cancer Center. To illustrate the role of cell signaling networks in sarcoma, we calculated twelve
pathway and process scores (apoptosis, cell cycle, DNA damage response, EMT, hormone receptor, hormone signaling (breast),
P13K/AKT, RAS/MAPK, RTK, TSC/MTOR, breast reactive and core reactive) based on a previously described method (Akbani
et al., 2014) (Figure S4D).Cell 171, 950–965.e1–e16, November 2, 2017 e12
iCluster
Integrative clustering using iCluster
In the investigation of subgroups within sarcoma, we integrated various molecular platforms by using iCluster, which formulates the
problem of subgroup discovery as a joint multivariate regression of multiple data types with reference to a set of common latent vari-
ables that represent the underlying tumor subtypes (Mo et al., 2013; Shen et al., 2009). The optimal combination of clusters was
determined minimizing a Bayesian information criterion.
Data processing
As input to iCluster, we used four molecular platforms: DNA copy number, DNA methylation, mRNA expression, and miRNA expres-
sion. Data were pre-processed using the following procedures. Copy number alteration data was derived from CBS segmented data
from the Affymetrix SNP6.0 array platform, and further reduced to a set of 4000 non-redundant regions as described (Mo et al.,
2013). For the methylation data (Illumina Infinium 450k arrays), the median absolute deviation was employed to select the top
4000 most variable CpG sites after beta-mixture quantile normalization (Pidsley et al., 2013). We removed methylation probes
with > 20% or more missing data and those corresponding to SNP and autosomal chromosomes. For mRNA and miRNA sequence
data, we excluded genes with low expression (based onmedian-normalized counts). Variance filtering led to 4000mRNAs and a var-
iable number of miRNAs for clustering. mRNA andmiRNA expression features were log2 transformed, normalized, and scaled before
inputting to iCluster.
iCoMut
Interactive visualization and exploration
Within a single graphic iCoMut (http://firebrowse.org/awg/sarc) was used to create graphics that display the comprehensive analysis
profile computed by Firehose (see next subsection); this enables readers to quickly infer co-occurring ormutually exclusive events for
the sarcoma cohort, plotted on a common x axis of sample IDs, across a pipeline of approximately 100 individual analysis tasks span-
ning 10 data modalities. iCoMut was used to create interactive figures that allow panels to be moved, sorted, searched, and even
extended with new data. These interactive figures are hosted on FireBrowse (http://firebrowse.org).
Data aggregation and analysis in Firehose began in the Broad Institute GDAC Firehose, an automated, high-throughput analysis
pipeline designed to systematize analyses from The Cancer Genome Atlas. Firehose first normalized clinical annotations and molec-
ular sample data, in the form of one file per sample, into analysis-ready aggregates (a single filewithmany samples) that can be imme-
diately fed into scientific codes with no further processing. These data packages were documented in detailed sample reports and
released to the public (https://gdac.broadinstitute.org/runs/sampleReports/latest), then fed into the analysis workflow (https://gdac.
broadinstitute.org/Analyses-DAG.html). Primary analyses were automatically performed for every data type of every cohort, such as:
significance assessment of mutations with MutSig and copy number alterations with GISTIC; functional analysis with Mutation
Assessor; analysis of mutagenesis by APOBEC cytidine deaminases; miR, mRNA, and protein expression cluster assignments using
both consensus hierarchical and consensus NMF methods; and pathway analyses with PARADIGM and GSEA. Statistical associa-
tions were automatically generated betweenmany of these results, and to the entire suite of clinical variables (e.g., survival) available
for the given cohort. q-values corresponding to FDR for individual gene mutations were computed by Mutsig2CV (Lawrence et al.,
2013). All results were integrated and made publicly available as: (a) online HTML reports citable in the literature by DOIs (https://
gdac.broadinstitute.org/runs/analyses__latest/reports), (b) the firebrowse.org portal and APIs (http://firebrowse.org/api-docs) and
(c) visual exploration tools such as IGV, the UCSC Genome Browser and cBioPortal. In the context of this paper, Firehose served
as first-pass analysis mechanism for the Sarcoma Analysis Working Group. In subsequent passes, custom data were integrated
from outside the Firehose automated data flow, including the more accurate cluster and pathway analysis results manually curated
by the Analysis Working Group.
Analysis feature matrix
As an intermediate step to rendering the iCoMut figure in FireBrowse, Firehose savedmajor analysis findings to a feature table (http://
firebrowse.org/api-docs/#!/Analyses/FeatureTable), which was then processed and converted into JSON to populate each of the
panels in the interactive display.
Regulome Explorer
Integrated analysis & interactive exploration
To gain greater insight into the development and progression of sarcomas, we integrated all of the data types produced by TCGA and
described in this paper into a single ‘‘feature matrix.’’ From this single heterogeneous dataset, significant pairwise associations were
inferred using statistical analysis and can be visually explored in a genomic context using Regulome Explorer, an interactive web
application (http://explorer.cancerregulome.org). In addition to associations that are inferred directly from the TCGA data, additional
sources of information and tools were integrated into the visualization for more extensive exploration (e.g., NCBI Gene, miRBase, the
UCSC Genome Browser, etc.).
Feature matrix construction
A feature matrix was constructed using all available clinical, sample, and molecular data for 206 unique patient/tumor samples. The
clinical information includes features such as age and tumor size; while the sample information includes features derived from mo-
lecular data such as single-platform cluster assignments. The molecular data includes mRNA and microRNA expression levelse13 Cell 171, 950–965.e1–e16, November 2, 2017
(Illumina HiSeq data), protein levels (RPPA data), copy number alterations (derived from segmented Affymetrix SNP data as well as
GISTIC regions of interest and arm-level values), DNA methylation levels (Illumina Infinium Methylation 450k array), and somatic
mutations. For mRNA expression data, gene-level RSEM values from RNA-seq were log2 transformed and filtered to remove low-
variability genes (bottom 25% removed, based on interdecile range). For miRNA expression data, the summed and normalized
microRNA quantification files were log2 transformed and filtered to remove low-variability microRNAs (bottom 25% removed, based
on interdecile range). For methylation data, probes were filtered to remove the bottom 25% based on interdecile range. For somatic
mutations, several binary mutation features indicating the presence or absence of a mutation in each sample were generated.
Mutation types considered were synonymous, missense, nonsense, and frameshift. Protein domains (InterPro) including any of these
mutation types were annotated as such, with nonsense and frameshift annotations being propagated to all subsequent protein
domains.
Pairwise statistical significance
Statistical association among the diverse data types in this study was evaluated by comparing pairs of features in the feature matrix.
Hypothesis testing was performed by testing against null models (i.e., absence of association), yielding a p-value. P-values for the
association between and among clinical and molecular data types were computed according to the nature of the data levels for
each pair: categorical versus categorical (Fisher’s exact test in the case of a 2x2 table, otherwise chi-square test); categorical versus
continuous (Kruskal-Wallis test) or continuous versus continuous (probability of a given Spearman correlation value). Ranked data
values were used in each case. To account for multiple-testing bias, the p-values were adjusted using the Bonferroni correction.
Regulome Explorer allows the user to interactively explore significant associations between various types of features – associa-
tions between molecular features (like miRNA expression and gene expression), associations between molecular features and
derived numeric features (like immune infiltration scores), and associations between molecular features and categorical features
such as clinical features or clusters derived from prior analysis (like iCluster).
PARADIGM
Integrated pathway analysis
Integration of copy number, mRNA expression, and pathway interaction data was performed on the 206 SARC samples using the
PARADIGM software (Sedgewick et al., 2013). Briefly, this procedure infers integrated pathway levels for genes, complexes, and pro-
cesses using pathway interactions and genomic and functional genomic data from each patient sample. Expression and gene copy
number data were obtained from Firehose. One was added to all expression values, which were then log2-transformed and median-
centered across samples for each gene. The log2-transformed, median-centered mRNA data were rank-transformed based on the
global ranking across all samples and all genes, then discretized (+1 for values with ranks in the highest tertile, 1 for values with
ranks in the lowest tertile, and 0 otherwise) prior to PARADIGM analysis.
Pathways were obtained in BioPax Level 3 format and included the NCIPID and BioCarta databases from https://pid.nci.nih.gov
and the Reactome database from http://reactome.org. Gene identifiers were unified by UniProt ID then converted to HumanGenome
Nomenclature Committee’s HUGO symbols using mappings provided by the committee (https://www.genenames.org/). Altogether,
1524 pathways were obtained. Interactions from all of these sources were then combined into a merged Superimposed Pathway
(SuperPathway). Genes, complexes, and abstract processes (e.g., ‘‘cell cycle’’ and ‘‘apoptosis’’) were retained and henceforth
referred to collectively as pathway features. The resulting pathway structure contained a total of 19504 features, representing
7369 proteins, 9354 complexes, 2092 protein families, 82 RNAs, 15 miRNAs, and 592 abstract processes.
The PARADIGM algorithm inferred an integrated pathway level (IPL) for each pathway feature; the IPL reflects the log likelihood of
the probability that each pathway feature is activated (versus inactivated). PARADIGM IPLs of the 19,504 features within the
SuperPathway are available on the GDC; (https://portal.gdc.cancer.gov/). An initial minimum variation filter (at least 1 sample with
absolute activity > 0.05) was applied, resulting in 15502 concepts (5898 proteins, 7307 complexes, 1916 families, 12 RNAs, 15
miRNAs and 354 abstract processes) with relative activities showing distinguishable variation across tumors.
Clustering of PARADIGM inferred pathways
Consensus clustering of the 206 SARC samples was based on the 3916most varying features (i.e., IPLs with variance within the high-
est quartile) so as to identify new subgroups on the basis of shared patterns of pathway inference. Consensus clustering was imple-
mented with the ConsensusClusterPlus package in R (Wilkerson and Hayes, 2010). Specifically, median-centered IPLs were used to
compute the squared Euclidean distance between samples, and this metric was used as the input to the ConsensusClusterPlus al-
gorithm. Hierarchical clustering using the Ward’s minimum variance method (i.e., ward inner linkage option) with 80% subsampling
was performed over 1000 iterations, and the final consensusmatrix was clustered using average linkage. The number of clusters was
selected by considering the relative change in the area under the empirical cumulative distribution function curve as well as the
average pairwise item-consensus within consensus clusters. We selected a cluster number of 5, as further separation provided min-
imal change and decreased thewithin-cluster consensus. In addition, consensus clusteringswithin LMS (n = 80), DDLPS (n = 50), and
MFS together with UPS (n = 61) were similarly performed.
Pathway features distinguishing each PARADIGM clusters (versus all others) were identified using the t test and Wilcoxon Rank
sum test with Benjamini-Hochberg FDR correction. Only features deemed significant (FDR-corrected p < 0.05) by both tests and
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the PARADIGM SuperPathway was assessed, and regulatory hubs with R 10 differentially activated downstream targets were
selected and displayed in a heatmap using the heatmap.plus package in R.
Differential pathway features in sarcoma
IPLs differentially activated between leiomyosarcoma (n = 80) and other sarcomas (n = 126) were identified using the t test and Wil-
coxon Rank Sum test with Benjamini-Hochberg FDR correction. Only features deemed significant (FDR-corrected p < 0.05) by both
tests and showing an absolute difference in groupmeans > 0.05 were selected. Sub-networks linking differentially activated features
through regulatory interactions within the PARADIGM SuperPathway structure were constructed and visualized using Cytoscape,
and regulatory hubs withR 10 differentially activated downstream targets were identified.
IPLs differentially activated between STLMS (n = 53) and ULMS (n = 27) were identified and features selected by the samemethod
as above. Differentially activated IPLs were then filtered by connectivity within the SuperPathway, such that only interconnected fea-
tures were retained. Pathway constituents of the PARADIGMSuperPathway enriched among these selected features were assessed
using the EASE score with Benjamini-Hochberg FDR correction, and sub-networks linking differentially activated features through
regulatory interactions were constructed and visualized using Cytoscape.
Quantitation of Nuclear Pleomorphism
Computational histologic analysis
Slide images were reviewed prior to analysis to remove those images containing scanning or preparation artifacts, or a significant
proportion of tumor-infiltrating lymphocytes. A total of 63 images were removed from this portion of the analysis for these reasons.
Slide images were analyzed at 20X objective resolution. Images scanned natively at 40X magnification were resized to 20X using a
bicubic interpolation. In total, over 500,000,000 cell nuclei were scored. Color was normalized to a standard H&E image using Rein-
hard color normalization that maps the LAB color space statistics of each image to the standard to improve the analysis consistency.
Normalized color images were unmixed using color deconvolution to digitally separate the hematoxylin (nuclear) and eosin stains.
Nuclear regions were identified by applying morphological reconstruction to the hematoxylin image, and a watershed transformation
was applied to separate closely packed nuclei. The area of each nucleus was thenmeasured in pixels and the area of each nucleus in
each slide recorded. A histogram of nuclear areaswas created for each patient with 100 bins of 12 pixels each. Statistical moments of
these histograms were calculated to capture the mean, variance, negative skew, and kurtosis of nuclear areas for each patient.
Histologic-genomic analysis
Several statistics were calculated formeasures of pleomorphism against genomic features, using copy number data fromSNP array–
basedmethods (see SNP-based copy number analysis, above). Specifically, ploidy, subclonal genome fraction (whichmeasures the
fraction of tumor genome that is not part of the ‘‘plurality’’ clone, and therefore is a reflection of increasing genomic complexity), and
genome doublings were calculated using the ABSOLUTE algorithm (Carter et al., 2012), and the number of unbalanced copy number
segments was defined as the total number of copy number segments with a log2 segment mean%0.1 orR 0.1 (level 3 seg file after
ISAR-correction [see section 2.1]).
To determine the alternative aneuploidy score [aneuploidy score’] (number of events) for each sample, the ABSOLUTE algorithm
was first used to determine the likeliest ploidy and absolute total copy number of each segment in the genome. Each segment was
designated as amplified, deleted, or neutral based on whether its copy number was greater than, smaller than, or equal to the sam-
ple’s ploidy (rounded to the nearest integer) respectively. For amplifications and deletions separately (collectively ‘‘alterations’’), seg-
ments were joined until either the entire chromosome was considered altered, or more than 20% of the genomic length between the
start and ends were not altered in the same direction; e.g., > 20% deleted or neutral for joining amplification segments. Alternative
aneuploidy score [aneuploidy score’](number of events) is calculated as the fewest possible arm- or chromosome-level events that
could have led from diploidy to the current allelic copy number state, including whole genome doubling events.
Statistical significance for correlations with histologic measures was calculated using the Pearson’s correlation, and statistical sig-
nificance for comparisons between tumors with different numbers of whole genome doubling was calculated using ANOVA.
QUANTIFICATION AND STATISTICAL ANALYSIS
Quantification details and statistical analysis methods for each of the various data platforms and for integrated analyses are
described in detail and referenced in their respective Method Details subsections.
DATA AND SOFTWARE AVAILABILITY
The raw data for TCGA SARC individual platforms, including DNA exome sequence, RNA expression sequence, miRNA expression
sequence, DNA methylation beta values, SNP array (copy number data), and RPPA proteomics data, as well as clinical data are
archived and publically available in the Genomic Data Commons (https://gdc.cancer.gov). Digital pathology images are also avail-
able at the Cancer Digital Slide Archive (http://cancer.digitalslidearchive.net/).
Software used for the analyses for each of the data platforms and integrated analyses are described and referenced in the indi-
vidual Method Details subsections and are listed in the Key Resource Table.e15 Cell 171, 950–965.e1–e16, November 2, 2017
ADDITIONAL RESOURCES
The TCGA SARC resource website is available at https://tcga-data.nci.nih.gov/docs/publications/sarc_2017/
Interactive tools for exploring the TCGA data have been developed by the Broad Institute (http://firebrowse.org, including the
iCoMut visualization tool http://firebrowse.org/awg/sarc/iCoMut/?cohort=SARC), Memorial Sloan Kettering Cancer Center (http://
www.cbioportal.org/), the Institute for Systems Biology (http://explorer.cancerregulome.org), and The University of Texas MD
Anderson Cancer Center (http://bioinformatics.mdanderson.org/tcgambatch/)Cell 171, 950–965.e1–e16, November 2, 2017 e16
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Figure S1. Tumor Reclassifications in Pathology Review and Genomic Alterations, Related to Figure 1
(A) Schematic of classification following expert pathology review of 237 submitted sarcoma samples, illustrating the challenge of accurate diagnosis in sarcoma
pathology, and the need for central pathology review in large-scale multi-institutional studies such as TCGA. Thirty-one cases (gray boxes) were excluded from
final analysis, including 5 tumors whichwere not sarcomas; 8whichwere considered to be tumors of inappropriate type (including the two desmoid tumors, which
(legend continued on next page)
were excluded from final analysis due to insufficient case numbers); 17 tumors for which a definite classification could not be made based on the available
material for review; and one DDLPS which was infiltrated by chronic lymphocytic lymphoma. A further 20 sarcomas were reclassified from one included type of
sarcoma to another, as indicated by lines.
(B) Copy-number alterations in sarcoma. The 206 sarcomas were subjected to unsupervised hierarchical clustering based on significantly amplified or deleted
regions across the genome (as determined by GISTIC 2.0), resulting in six distinct genomic clusters. From left to right: DDLPS CIN, a group consisting almost
exclusively of DDLPS, with hallmark amplicons in chromosome 12q and also various other SCNAs across the genome; quiet, which contains all but one of the
synovial sarcomas as well as genomically stable DDLPS and other copy-number–quiet tumors; LMS quiet, characterized by chromosomal or arm-level deletions
but relatively few other SCNAs; LMS CIN, LMS with more chromosomal instability than those in LMS quiet; UPS/MFS 1, a highly chromosomally unstable group
enriched for UPS and MFS; and UPS/MFS 2, another group enriched for UPS and MFS. UPS/MFS 1 and 2 are distinguished by different frequencies of SCNAs,
including more RB1 focal deletions in UPS/MFS1 and more chromosome 8p and 9p deletions in UPS/MFS 2.
C) Number of unbalanced segments for each tumor plotted for each TCGA cohort and for each sarcoma histologic type included in the sarcoma TCGA. Sarcoma
types are boxed.
(D) Number of nonsynonymous somatic mutations versus number of unbalanced segments mapped for each individual sarcoma case (color coded by histologic
type) and, for comparison, a randomly chosen 10% of all other TCGA specimens.
(E) TERT expression plotted against TERT copy-number alterations. Mutations and identified TRIO-TERT fusions are indicated.
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(legend on next page)
Figure S2. Pansarcoma Mutational Profiling, Related to Figure 2
(A) Types of somatic mutations detected by whole-exome sequencing of the 206 sarcomas. In total, 11,096 somatic mutations were detected, including 10,437
point mutations and 659 insertions/deletions (indels). Point mutations included 2624 silent, 7130 missense, 442 nonsense, 17 read-through, and 224 splice-site
mutations.
(B) De-novo mutational signatures identified using a Bayesian variant of non-negative matrix factorization (Kasar et al., 2015). Top, signatures extracted from 205
WES samples, identifying two major mutational processes. The first signature (SIG.WES1), characterized by a broad spectrum of base substitutions, is most
similar to the COSMIC5 signature (http://cancer.sanger.ac.uk/cosmic/signatures) (cosine similarity = 0.8). The second signature (SIG.WES2) had dominant C > T
mutations at CpG di-nucleotide sites; this signature is most similar to COSMIC1 (cosine similarity = 0.93) and COSMIC6 (cosine similarity = 0.85). COSMIC1 is
caused by spontaneous cytosine deamination. COSMIC6 is associatedwith defective DNAmismatch repair and is present inmicrosatellite-unstable tumors. This
signature was high in two tumors with the highest mutation burden (TCGA-DX-AB32 and TCGA-3B-A9HT), explaining 80% of all mutations in these two samples,
compared with 9% of mutations in the remaining samples. Bottom, de-novo mutational signatures in coding regions extracted from 37 WGS samples. Two
signatures (SIG.WGS1 and SIG.WGS3) were similar to those observed in WES samples. The additional signatures were SIG.WGS2, characteristic of dominant
C > Tmutations at TCW (W = A/T) contexts, and SIG.WGS4, with C > Gmutations at TCW contexts. These two signatures were most similar to COSMIC2 (cosine
similarity = 0.73) and COSMIC13 (cosine similarity = 0.79), respectively, which are attributed to the mutagenesis of the AID/APOBEC family of cytidine de-
aminases, indicating a minor role of APOBEC mutagenesis in SARC tumors in addition to COSMIC1 and 5.
(C) Scatterplots of the signature activity: number of mutations assigned to SIG.WES2 in (B) (with a pseudocount of one added to permit log transformation) versus
mRNA levels of MSH6 (top) andMSH2 (bottom)measured by log2(fold change against median across tumors). The boxes highlight the two hyper mutant, putative
microsatellite instability (MSI) samples, AB32 (UPS) and A9HT (STLMS). AB32 had a frameshift mutation inMSH6. A9HT had nomutations in detected in the DNA
mismatch repair genesMLH1,MSH2,MSH3, orMSH6, but had the lowest MSH2 expression and had a significant enrichment of 1-base insertions and deletions
(14% versus mean 3% in remaining samples).
(D) Pearson correlation between age at diagnosis and the combined activity of COSMIC1 and COSMIC5 signatures across 203 WES samples, by sarcoma type.
Correlation coefficients and p values are as follows: All sarcoma 0.34, p < 0.00001; DDLPS 0.38, p = 0.006; MFS 0.52, p = 0.04; MPNST0.38, p = 0.53; SS 0.45,
p = 0.2; STLMS 0.43, p = 0.001; ULMS 0.35, p = 0.07; UPS 0.02, p = 0.9.
(E) Analysis of nuclear area. Image analysis algorithmswere used tomeasure the sizes of over 500,000,000 cell nuclei in digitized sarcoma tissues. Distributions of
nuclear area shown here are from a UPS (TCGA-DX-A8BM – red) and a synovial sarcoma (TCGA-DX-A7EQ – blue). The UPS contained larger and more het-
erogeneous nuclei, as can be seen from the longer area distribution tail.
(F) The variance measure of nuclear area was significantly associated with subclonal genome fraction (left) and with an aneuploidy score based on the number of
arms with gains or losses (Aneuploidy score’) (right), by Pearson correlation.
(legend on next page)
Figure S3. Genomic and Epigenetic Alterations across Sarcoma Types, Related to Figure 3
(A) Results of cluster analyses. Shown are tumor histology, copy-number alteration clustering, DNA methylation clustering, mRNA clustering, miRNA clustering
excluding LMS samples, RPPA (protein) clustering, PARADIGM integrative clustering (copy number, mRNA expression, and pathway interaction data), and
iCluster integrative clustering (DNA copy number, DNAmethylation, mRNA expression, andmiRNA expression). Individual tumors are shown in the same order as
in Figure 1A. The displayed miRNA clustering excluded the LMS samples because (as can be seen in [C]) they differed very strongly from other tumor types. As
miRNA clustering was based on the 25% most variable miRNAs between samples, LMS could not be included since its markedly different miRNA expression
profile relative to the other sarcomas overly limited the ability of the model to reliably cluster the remaining tumors.
(B) DNA methylation signatures in sarcoma. Left, unsupervised clustering of the 206 sarcomas based on DNA methylation, performed using the most variable
CpG loci on the Illumina Infinium HM450 array. From left to right, the clusters are: M1, mixed DDLPS, UPS, MFS, and STLMS with high leukocyte fraction, 5-year
OS 54%; M2, synovial sarcoma with 5-year OS < 24%; M3, predominantly STLMS, with good outcomes and 5-year OS 61%; M4, UPS/MFS with 5-year OS 0%;
and M5, ULMS and DDLPS with poor outcomes and 5-year OS < 33%. Right, leukocyte fraction by methylation cluster.
(C) miRNA signatures in sarcoma. Left panel: unsupervised hierarchical clustering using the top 25%most variable miRNAs across all 206 sarcomas. The analysis
yielded 2 distinct clusters with very high concordance with LMS and nonLMS types, demonstrating that LMS (both uterine and soft tissue) have a very distinct
miRNA profile from the other TCGA sarcoma types. Right panel: Cluster analysis of the 126 nonLMS samples, using the top 25%most variable miRNAswithin the
nonLMS types (DDLPS, MFS, MPNST, SS, and UPS). This resulted in a 3-cluster solution that was highly concordant with histology type: UPS/MFS, synovial,
and DDLPS.
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Figure S4. Gene and Protein Expression Alterations across Sarcoma Types, Related to Figure 3
(A) mRNA expression profile distinguishes LMS from other sarcoma types. Unsupervised pansarcoma mRNA expression clustering of the most variable genes
across 206 sarcomas (2,038 genes; standard deviationR 2.0) yielded 3 stable clusters. From left to right: Cluster 3, composed almost entirely of LMS tumors and
having a unique expression profile; Cluster 1, predominantly DDLPS, SS, andMPNST; Cluster 2, predominantly DDLPS, UPS andMFS. A subset of genes, largely
associated with inflammatory signatures, did not correlate with histology and were either ubiquitously on or off, with low expression in cluster 1 and high in
cluster 2 (see also Figure 7A).
(B) Projection of 237 soft tissue sarcomas on a 2-D tumor ‘‘map’’ visualization of high-dimensional mRNA expression data. We also mapped the 31 cases that
pathology review excluded from the final analysis (black dots) and cases that failed TCGA QC (gray dots). The excluded cases largely clustered with the included
cases, consistent with their largely mesenchymal origin, despite some being of uncertain or inappropriate type. Among the included sarcomas, leiomyosarcomas
(STLMS and ULMS) clustered together (lower right), while synovial sarcomas also formed a distinct cluster (left). The remaining sarcomas largely clustered
together (as was seen in other platforms) with mixing of DDLPS, UPS and MFS. UPS appeared to separate into two major groups, one of which was more similar
to DDLPS, and the second was more similar to MFS.
(C) Correlation of RPPA protein expression profiles with histologic type. Unsupervised pansarcoma cluster analysis on RPPA data from 173 samples analyzed
with 192 antibodies yielded 5 stable clusters that showed statistically significant association with leukocyte fraction and histologic type (chi-square p values
shown). The annotation bars shown above the heatmap were not used for clustering. Cluster 1 (at left) contained predominantly leiomyosarcoma, while clus-
ters 2-5 each contained a mixture of sarcoma types.
(D) Scores for therapeutically and prognostically relevant pathways commonly activated in malignancy were correlated with sarcoma RPPA clusters. The
boxplots show pathway scores for each of the 5 RPPA clusters. p values are based on the ANOVA test for differences across the clusters. Relative to the other
clusters, C1 (LMS-predominate, light blue) demonstrated high PI3K/AKT pathway and low apoptosis and RTK pathways. C4 (dark green) was characterized by
high apoptosis, RTK, and DNA damage response pathways. In addition, C3 (light green, including all SS and MPNST) exhibited high hormone signaling and low
PI3K/AKT, RAS/MAPK, breast reactive, and core reactive pathways, whereas C5 (gold, UPS/DDLPS) was high in apoptosis and EMT pathways and low in cell
cycle and TSC/MTOR pathway activation.
Figure S5. Copy Number and Methylation Alterations in DDLPS, Related to Figure 4
(A) Unsupervised clustering of DDLPS samples based on copy number alterations. Upper left panel, unsupervised clustering of the 50 DDLPS by copy number
(GISTIC2.0 analysis from AffySNP 6.0) showed threemain copy number clusters. Lower left panel, SCNA frequency plots for each of the three clusters, displaying
the percentage of cases in the cohort using GISTIC 2.0 thresholded copy number assignment +2 (amplification) or 2 (deep deletion). Green lines mark the
arbitrary threshold frequency of 5%. Red arrowsmark each cluster’s prominent SCNAs and the genes contained in them: the 6q25.1 amplification containingUST
and SASH1 in K3, the 1p32.1 amplification containing JUN in K1, and 1q24.3 (DNM3,MIR214) and 5p15.33 (TERT) amplifications in K2. Fisher’s test was used to
compare differences in rates of occurrence across different clusters, and the reported q-values were obtained after Benjamini-Hochberg correction for multiple
hypotheses. Upper right panel, disease-specific survival according to copy number cluster. Lower right panels, expression of TERT and JUN in each copy
number cluster.
(B) Graphs showing the association of highly methylated Meth2 cluster with poor DSS, low leukocyte fraction, and increased Th2 cells.
(C) Boxplot showing immature dendritic cell score in DDLPS by integrated copy number and methylation clusters.
(legend on next page)
Figure S6. Activated Pathways and Copy-Number Alterations in LMS and Histologic Spectrum and Prognostic Factors in UPS/MFS, Related
to Figures 1, 5, and 6
(A) Pathway activation in LMS. The plots show RPPA pathway scores calculated for the 173 tumors for which RPPA results are available. LMS, compared with
other sarcoma types, had higher AKT score (p = 4e-06), higher hormone response score (p = 0.00015), and lower apoptosis score (p = 1e-05; p values are t test, all
LMS versus all other sarcomas). The difference in AKT score was largely driven by STLMS, and difference in hormone response scores was largely driven by
ULMS; the higher AKT response score in ULMS and hormone response score in STLMS compared to other sarcoma types were not significant (p = 0.09 and
p = 0.068, respectively, Tukey test). Apoptosis scores were lower in both STLMS and ULMS compared to other sarcomas (p < 0.0001, Tukey test).
(B) Prognostic value of miR-181b-5p. Kaplan-Meier curve for RFS is shown for patients with tumors having miR-181b-5p abundance above and below the
optimized cutoff (Budczies et al., 2012). The p value shown was adjusted for the cutoff finder and multiple testing.
(C) DNA damage and hypoxia response scores in ULMS and STLMS. First panel, HIF1amRNA expression in STLMS relative to ULMS (t test, p = 9e-06). Second
panel, HIF1a target gene expression signature (mRNA) correlated with HIF1a expression and was higher in STLMS (t test p = 6e-05). Third panel, RPPA DNA
damage response score was higher in ULMS (t test p = 0.005).
(D) Thresholded copy number frequency analysis (GISTIC) of STLMS iCluster C1 versus C2. Fisher’s test was used to compare differences in rates of occurrence
across different clusters, and q-values were obtained after Benjamini-Hochberg correction for multiple hypotheses. Arrow indicates a focal region (17p11.2 to
17p12) with significantly different copy number between C1 and C2 (q-value: 0.022). Genes from this locus include SLC5A10, FAM83G, GRAP, LOC388436,
LOC79999, GRAPL, EPN2, EPN2-IT1, EPN2-AS1, B9D1, MIR1180, MAPK7, MFAP4, MYOCD, LOC101928418, LOC100128006, and ARHGAP44.
(E) Histologic spectrum of UPS/MFS. Top left panel, classic area of low-gradeMFS. Top right panel, MFS showing transition from classic low grade to high-grade
UPS-likemorphology. Lower left panel, high-grade area ofMFS histologically indistinguishable from classic UPS. Lower right panel, classic UPS. All images were
captured at 200x magnification (TCGA digital slide scans, Aperio Imagescope. Scale bar, 200 mm).
(F) Multivariable miRNA prognostic classifier for metastasis-free survival. We performed a LASSO penalized regression analysis using all miRNAs and tumor size
in 54 UPS/MFS samples to identify sets of miRNAs and coefficients that would best predict metastasis-free survival. The samples were split into high and low
groups based on their model score at a cutpoint that minimized the log-rank p value. p value shown is corrected for multiple testing.
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Figure S7. Immune Infiltration and Targetable Immune Markers Correlate with Sarcoma Type and Immune Score, Related to Figure 7
(A) Boxplots showing the distribution of selected immune signatures by histology. Macrophage score: p < 0.008 for UPS/MFS or DDLPS versus other sarcomas in
all pairwise comparisons. CD8: p < 0.005 for DDLPS versus other sarcoma types in all pairwise comparisons. PD-L1: p < 0.032 for STMLS versus other sarcomas
in all pairwise combinations.
(legend continued on next page)
(B) Validation of immune scores in LMS, MFS, and SS. Scatterplots show the median immune infiltration score for each immune signature with TCGA data
displayed on the x axis and the validation data from Lesluyes et al. displayed on the y axis. The Spearman correlation coefficient is shown for each.
(C) Validation of CD8, NK and TH2 immune scores for DDLPS and UPS. Plots show scores for each individual tumor in the Lesluyes et al. cohort or the TCGA
cohort, demonstrating similar distribution of scores between the datasets.
(D) Expression of three druggable immune targets in tumors ordered by sarcoma type. Expression of each differed significantly among the sarcoma types
(p = 1.6e-15 for B7-H3, 9.8e-11 for TGFB1, and 2.9e-14 for TIM3 by Kruskal-Wallis test).
